Schultz et al. (1998) Proc. Natl. Acad. Sci. USA 95, 5857-5864
Letunic et al. (2012) Nucleic Acids Res , doi:10.1093/nar/gkr931

• HOME
• SETUP
• FAQ
• ABOUT
• GLOSSARY
• WHAT'S NEW
• FEEDBACK

S_TKc Serine/Threonine protein kinases, catalytic domain

SMART accession number:	SM00220
Description:	Phosphotransferases. Serine or threonine-specific kinase subfamily.
Interpro abstract (IPR002290):	Protein phosphorylation, which plays a key role in most cellular activities, is a reversible process mediated by protein kinases and phosphoprotein phosphatases. Protein kinases catalyse the transfer of the gamma phosphate from nucleotide triphosphates (often ATP) to one or more amino acid residues in a protein substrate side chain, resulting in a conformational change affecting protein function. Phosphoprotein phosphatases catalyse the reverse process. Protein kinases fall into three broad classes, characterised with respect to substrate specificity [(PUBMED:3291115)]: Serine/threonine-protein kinases Tyrosine-protein kinases Dual specificity protein kinases (e.g. MEK - phosphorylates both Thr and Tyr on target proteins) Protein kinase function is evolutionarily conserved from Escherichia coli to human [(PUBMED:12471243)]. Protein kinases play a role in a multitude of cellular processes, including division, proliferation, apoptosis, and differentiation [(PUBMED:12368087)]. Phosphorylation usually results in a functional change of the target protein by changing enzyme activity, cellular location, or association with other proteins. The catalytic subunits of protein kinases are highly conserved, and several structures have been solved [(PUBMED:15078142)], leading to large screens to develop kinase-specific inhibitors for the treatments of a number of diseases [(PUBMED:15320712)]. Eukaryotic protein kinases [, (PUBMED:7768349), (PUBMED:1835513), (PUBMED:1956325), (PUBMED:3291115)] are enzymes that belong to a very extensive family of proteins which share a conserved catalytic core common with both serine/threonine and tyrosine protein kinases. There are a number of conserved regions in the catalytic domain of protein kinases. In the N-terminal extremity of the catalytic domain there is a glycine-rich stretch of residues in the vicinity of a lysine residue, which has been shown to be involved in ATP binding. In the central part of the catalytic domain there is a conserved aspartic acid residue which is important for the catalytic activity of the enzyme [(PUBMED:1862342)]. This entry represents the protein kinase catalytic domain found in a number of serine/threonine-protein kinases and dual specificity protein kinases.
GO process:	protein phosphorylation (GO:0006468)
GO function:	protein kinase activity (GO:0004672), ATP binding (GO:0005524)
Family alignment:	View or CHROMA formatCLUSTALW formatMSF formatFASTA formatPIR format

There are 22857 S_TKc domains in 22657 proteins in SMART's nrdb database.

Click on the following links for more information.

• Evolution (species in which this domain is found)

• Click on to expand nodes. To display all proteins with a S_TKc domain in a specific node, click on it.

  This tree shows only several representative species. The complete taxonomic breakdown of all proteins with S_TKc domain is also avaliable.

  Useful shortcuts: Expand all nodes or Collapse tree
  Go to specific node: Anopheles gambiae, Arabidopsis thaliana, Caenorhabditis elegans, Drosophila melanogaster, Homo sapiens, Mus musculus, Rattus norvegicus, Saccharomyces cerevisiae, Takifugu rubripes

• Cellular role (predicted cellular role)

• Binding / catalysis: serine-specific phosphotransferase, threonine-specific phosphotransferase

• Literature (relevant references for this domain)

• Primary literature is listed below; Automatically-derived, secondary literature is also avaliable.

  • Lewis TS, Shapiro PS, Ahn NG
  • Signal transduction through MAP kinase cascades.
  • Adv Cancer Res. 1998; 74: 49-139

  • Engh RA, Girod A, Kinzel V, Huber R, Bossemeyer D
  • Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity.
  • J Biol Chem. 1996; 271: 26157-64
  • Display abstract

  • The discovery of several hundred different protein kinases involved in highly diverse cellular signaling pathways is in stark contrast to the much smaller number of known modulators of cell signaling. Of these, the H series protein kinase inhibitors (1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7), N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide (H8) N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89)) are frequently used to block signaling pathways in studies of cellular regulation. To elucidate inhibition mechanisms at atomic resolution and to enable structure-based drug design of potential therapeutic modulators of signaling pathways, we determined the crystal structures of corresponding complexes with the cAPK catalytic subunit. Complexes with H7 and H8 (2.2 A) and with H89 (2.3 A) define the binding mode of the isoquinoline-sulfonamide derivatives in the ATP-binding site while demonstrating effects of ligand-induced structural change. Specific interactions between the enzyme and the inhibitors include the isoquinoline ring nitrogen ligating to backbone amide of Val-123 and an inhibitor side chain amide bonding to the backbone carbonyl of Glu-170. The conservation of the ATP-binding site of protein kinases allows evaluation of factors governing general selectivity of these inhibitors among kinases. These results should assist efforts in the design of protein kinase inhibitors with specific properties.

  • Hanks SK, Hunter T
  • Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification.
  • FASEB J. 1995; 9: 576-96
  • Display abstract

  • The eukaryotic protein kinases make up a large superfamily of homologous proteins. They are related by virtue of their kinase domains (also known as catalytic domains), which consist of approximately 250-300 amino acid residues. The kinase domains that define this group of enzymes contain 12 conserved subdomains that fold into a common catalytic core structure, as revealed by the 3-dimensional structures of several protein-serine kinases. There are two main subdivisions within the superfamily: the protein-serine/threonine kinases and the protein-tyrosine kinases. A classification scheme can be founded on a kinase domain phylogeny, which reveals families of enzymes that have related substrate specificities and modes of regulation.

  • Owen DJ, Noble ME, Garman EF, Papageorgiou AC, Johnson LN
  • Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product.
  • Structure. 1995; 3: 467-82
  • Display abstract

  • BACKGROUND: Control of intracellular events by protein phosphorylation is promoted by specific protein kinases. All the known protein kinase possess a common structure that defines a catalytically competent entity termed the 'kinase catalytic core'. Within this common structural framework each kinase displays its own unique substrate specificity, and a regulatory mechanism that may be modulated by association with other proteins. Structural studies of phosphorylase kinase (Phk), the major substrate of which is glycogen phosphorylase, may be expected to shed light on its regulation. RESULTS: We report two crystal structures of the catalytic core (residues 1-298; Phk gamma trnc) of the gamma-subunit of rabbit muscle phosphorylase kinase: the binary complex with Mn2+/beta-gamma-imidoadenosine 5'-triphosphate (AMPPNP) to a resolution of 2.6 A and the binary complex with Mg2+/ADP to a resolution of 3.0 A. The structures were solved by molecular replacement using the cAMP-dependent protein kinase (cAPK) as a model. CONCLUSIONS: The overall structure of Phk gamma trnc is similar to that of the catalytic core of other protein kinases. It consists of two domians joined on one edge by a 'hinge', with the catalytic site located in the cleft between the domains. Phk gamma trnc is constitutively active, and lacks the need for an activatory phosphorylation event that is essential for many kinases. The structure exhibits an essentially 'closed' conformation of the domains which is similar to that of cAPK complexed with substrates. The phosphorylated residue that is located at the domain interface in many protein kinases and that is believed to stabilize an active conformation is substituted by a glutamate in Phk gamma trnc. The glutamate, in a similar manner to the phosphorylated residue in other protein kinases, interacts with an arginine adjacent to the catalytic aspartate but does not participate in interdomain contacts. The interactions between the enzyme and the nucleotide product of its activity, Mg2+/ADP, explain the inhibitory properties of the nucleotides that are observed in kinetic studies.

  • Schulze-Gahmen U et al.
  • Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine.
  • Proteins. 1995; 22: 378-91
  • Display abstract

  • Cyclin-dependent kinases (CDKs) are conserved regulators of the eukaryotic cell cycle with different isoforms controlling specific phases of the cell cycle. Mitogenic or growth inhibitory signals are mediated, respectively, by activation or inhibition of CDKs which phosphorylate proteins associated with the cell cycle. The central role of CDKs in cell cycle regulation makes them a potential new target for inhibitory molecules with anti-proliferative and/or anti-neoplastic effects. We describe the crystal structures of the complexes of CDK2 with a weakly specific CDK inhibitor, N6-(delta 2-isopentenyl)adenine, and a strongly specific inhibitor, olomoucine. Both inhibitors are adenine derivatives and bind in the adenine binding pocket of CDK2, but in an unexpected and different orientation from the adenine of the authentic ligand ATP. The N6-benzyl substituent in olomoucine binds outside the conserved binding pocket and is most likely responsible for its specificity. The structural information from the CDK2-olomoucine complex will be useful in directing the search for the next generation inhibitors with improved properties.

  • Zhang J, Zhang F, Ebert D, Cobb MH, Goldsmith EJ
  • Activity of the MAP kinase ERK2 is controlled by a flexible surface loop.
  • Structure. 1995; 3: 299-307
  • Display abstract

  • BACKGROUND: The mitogen-activated protein (MAP) kinase, ERK2, is a tightly regulated enzyme in the ubiquitous Ras-activated protein kinase cascade. ERK2 is activated by phosphorylation at two sites, Y185 and T183, that lie in the phosphorylation lip at the mouth of the catalytic site. To ascertain the role of these two residues in securing the low-activity conformation of the enzymes we have carried out crystallographic analyses and assays of phosphorylation-site mutants of ERK2. RESULTS: The crystal structures of four mutants, T183E (threonine at residue 183 is replaced by glutamate), Y185E, Y185F and the double mutant T183E/Y185E, were determined. When T183 is replaced by glutamate, few conformational changes are observed. By contrast, when Y185 is replaced by glutamate, 19 residues become disordered, including the entire phosphorylation lip and an adjacent loop. The conservative substitution of phenylalanine for Y185 also induces relatively large conformational changes. A binding site for phosphotyrosine in the active enzyme is putatively identified on the basis of the high-resolution refinement of the structure of wild-type ERK2. CONCLUSIONS: The remarkable disorder observed throughout the phosphorylation lip when Y185 is mutated shows that the stability of the phosphorylation lip is rather low. Therefore, only modest amounts of binding energy will be required to dislodge the lip for phosphorylation, and it is likely that these residues will be involved in conformational changes associated with both with binding to kinases and phosphatases and with activation. Furthermore, the low-activity structure is specifically dependent on Y185, whereas there is no such dependency on T183. Both residues, however, participate in forming the active enzyme, contributing to its tight control.

  • Taylor SS, Radzio-Andzelm E
  • Three protein kinase structures define a common motif.
  • Structure. 1994; 2: 345-55
  • Display abstract

  • Structural comparisons between cAMP-dependent protein kinase, cyclin-dependent kinase 2 and mitogen-activated protein kinase reveal which features are common to the protein kinase family and which are enzyme-specific.

  • Zhang F, Strand A, Robbins D, Cobb MH, Goldsmith EJ
  • Atomic structure of the MAP kinase ERK2 at 2.3 A resolution.
  • Nature. 1994; 367: 704-11
  • Display abstract

  • The structure of the MAP kinase ERK2, a ubiquitous protein kinase target for regulation by Ras and Raf, has been solved in its unphosphorylated low-activity conformation to a resolution of 2.3 A. The two domains of unphosphorylated ERK2 are farther apart than in the active conformation of cAMP-dependent protein kinase and the peptide-binding site is blocked by tyrosine 185, one of the two residues that are phosphorylated in the active enzyme. Activation of ERK2 is thus likely to involve both global and local conformational changes.

  • Bossemeyer D, Engh RA, Kinzel V, Ponstingl H, Huber R
  • Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5-24).
  • EMBO J. 1993; 12: 849-59
  • Display abstract

  • The crystal structure of the porcine heart catalytic subunit of cAMP-dependent protein kinase in a ternary complex with the MgATP analogue MnAMP-PNP and a pseudosubstrate inhibitor peptide, PKI(5-24), has been solved at 2.0 A resolution from monoclinic crystals of the catalytic subunit isoform CA. The refinement is presently at an R factor of 0.194 and the active site of the molecule is well defined. The glycine-rich phosphate anchor of the nucleotide binding fold motif of the protein kinase is a beta ribbon acting as a flap with conformational flexibility over the triphosphate group. The glycines seem to be conserved to avoid steric clash with ATP. The known synergistic effects of substrate binding can be explained by hydrogen bonds present only in the ternary complex. Implications for the kinetic scheme of binding order are discussed. The structure is assumed to represent a phosphotransfer competent conformation. The invariant conserved residue Asp166 is proposed to be the catalytic base and Lys168 to stabilize the transition state. In some tyrosine kinases Lys168 is functionally replaced by an Arg displaced by two residues in the primary sequence, suggesting invariance in three-dimensional space. The structure supports an in-line transfer with a pentacoordinate transition state at the phosphorus with very few nuclear movements.

  • DeBondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH
  • Crystal structure of cyclin-dependent kinase 2.
  • Nature. 1993; 363: 595-602
  • Display abstract

  • Cyclin-dependent kinase 2 (CDK2) is a member of a highly conserved family of protein kinases that regulate the eukaryotic cell cycle. The crystal structures of the human CDK2 apoenzyme and its Mg2+ ATP complex have been determined to 2.4 A resolution. The structure is bi-lobate, like that of the cyclic AMP-dependent protein kinase, but contains a unique helix-loop segment that interferes with ATP and protein substrate binding and probably plays a key part in the regulation of all cyclin-dependent kinases.

  • Zheng J et al.
  • Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor.
  • Biochemistry. 1993; 32: 2154-61
  • Display abstract

  • The structure of a ternary complex of the catalytic subunit of cAMP-dependent protein kinase, MgATP, and a 20-residue inhibitor peptide was determined at a resolution of 2.7 A using the difference Fourier technique starting from the model of the binary complex (Knighton et al., 1991a). The model of the ternary complex was refined using both X-PLOR and TNT to an R factor of 0.212 and 0.224, respectively. The orientation of the nucleotide and the interactions of MgATP with numerous conserved residues at the active site of the enzyme are clearly defined. The unique protein kinase nucleotide binding site consists of a five-stranded antiparallel beta-sheet with the base buried in a hydrophobic site along beta-strands 1 and 2 and fixed by hydrogen bonds to the N6 amino and N7 nitrogens. The small lobe secures the nucleotide via a glycine-rich loop and by ion pairing with Lys72 and Glu91. While the small lobe fixes the nontransferable alpha- and beta-phosphates in this inhibitor complex, the gamma-phosphate is secured by two Mg2+ ions and interacts both directly and indirectly with several residues in the large lobe--Asp184, Asn171, Lys168. Asp166 is positioned to serve as a catalytic base. The structure is correlated with previous chemical evidence, and the features that distinguish this nucleotide binding motif from other nucleotide binding proteins are delineated.

  • Knighton DR, Zheng JH, TenEyck LF, Xuong NH, Taylor SS, Sowadski JM
  • Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase.
  • Science. 1991; 253: 414-20
  • Display abstract

  • The structure of a 20-amino acid peptide inhibitor bound to the catalytic subunit of cyclic AMP-dependent protein kinase, and its interactions with the enzyme, are described. The x-ray crystal structure of the complex is the basis of the analysis. The peptide inhibitor, derived from a naturally occurring heat-stable protein kinase inhibitor, contains an amphipathic helix that is followed by a turn and an extended conformation. The extended region occupies the cleft between the two lobes of the enzyme and contains a five-residue consensus recognition sequence common to all substrates and peptide inhibitors of the catalytic subunit. The helical portion of the peptide binds to a hydrophobic groove and conveys high affinity binding. Loops from both domains converge at the active site and contribute to a network of conserved residues at the sites of magnesium adenosine triphosphate binding and catalysis. Amino acids associated with peptide recognition, nonconserved, extend over a large surface area.

  • Knighton DR et al.
  • Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase.
  • Science. 1991; 253: 407-14
  • Display abstract

  • The crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase complexed with a 20-amino acid substrate analog inhibitor has been solved and partially refined at 2.7 A resolution to an R factor of 0.212. The magnesium adenosine triphosphate (MgATP) binding site was located by difference Fourier synthesis. The enzyme structure is bilobal with a deep cleft between the lobes. The cleft is filled by MgATP and a portion of the inhibitor peptide. The smaller lobe, consisting mostly of amino-terminal sequence, is associated with nucleotide binding, and its largely antiparallel beta sheet architecture constitutes an unusual nucleotide binding motif. The larger lobe is dominated by helical structure with a single beta sheet at the domain interface. This lobe is primarily involved in peptide binding and catalysis. Residues 40 through 280 constitute a conserved catalytic core that is shared by more than 100 protein kinases. Most of the invariant amino acids in this conserved catalytic core are clustered at the sites of nucleotide binding and catalysis.

  • Weber IT, Steitz TA, Bubis J, Taylor SS
  • Predicted structures of cAMP binding domains of type I and II regulatory subunits of cAMP-dependent protein kinase.
  • Biochemistry. 1987; 26: 343-51
  • Display abstract

  • The mammalian cAMP-dependent protein kinases have regulatory (R) subunits that show substantial homology in amino acid sequence with the catabolite gene activator protein (CAP), a cAMP-dependent gene regulatory protein from Escherichia coli. Each R subunit has two in-tandem cAMP binding domains, and the structure of each of these domains has been modeled by analogy with the crystal structure of CAP. Both the type I and II regulatory subunits have been considered, so that four cAMP binding domains have been modeled. The binding of cAMP in general is analogous in all the structures and has been correlated with previous results based on photolabeling and binding of cAMP analogues. The model predicts that the first cAMP binding domain correlates with the previously defined fast dissociation site, which preferentially binds N6-substituted analogues of cAMP. The second domain corresponds to the slow dissociation site, which has a preference for C8-substituted analogues. The model also is consistent with cAMP binding in the syn conformation in both sites. Finally, this model has targeted specific regions that are likely to be involved in interdomain contacts. This includes contacts between the two cAMP binding domains as well as contacts with the amino-terminal region of the R subunit and with the catalytic subunit.

• Disease (disease genes where sequence variants are found in this domain)

• SwissProt sequences and OMIM curated human diseases associated with missense mutations within the S_TKc domain.

  Protein	Disease
  TGF-beta receptor type-2 (P37173) (SMART)	OMIM:190182: Colon cancer ; Colorectal cancer, hereditary nonpolyposis, type 6 OMIM:114500: Esophageal cancer OMIM:133239:
  Phosphorylase b kinase gamma catalytic chain, testis/liver isoform (P15735) (SMART)	OMIM:172471: Glycogenosis, hepatic, autosomal
  Rhodopsin kinase (Q15835) (SMART)	OMIM:180381: Oguchi disease-2 OMIM:258100:
  Tyrosine-protein kinase BTK (Q06187) (SMART)	OMIM:300300: Agammaglobulinemia, type 1, X-linked ; ?XLA and isolated growth hormone deficiency OMIM:307200:
  Insulin receptor subunit beta (P06213) (SMART)	OMIM:147670: Leprechaunism OMIM:246200: Rabson-Mendenhall syndrome OMIM:262190: Diabetes mellitus, insulin-resistant, with acanthosis nigricans
  Tyrosine-protein kinase ZAP-70 (P43403) (SMART)	OMIM:176947: Selective T-cell defect
  Serine/threonine-protein kinase receptor R3 (P37023) (SMART)	OMIM:601284: Hereditary hemorrhagic telangiectasia-2 OMIM:600376:
  High affinity nerve growth factor receptor (P04629) (SMART)	OMIM:191315: Insensitivity to pain, congenital, with anhidrosis OMIM:256800: Medullary thyroid carcinoma, familial OMIM:155240:
  Retinal guanylyl cyclase 1 (Q02846) (SMART)	OMIM:601777: Cone dystrophy, progressive OMIM:600179: Leber congenital amaurosis, type I OMIM:204000: Cone-rod dystrophy 6 OMIM:601777:
  Ribosomal protein S6 kinase alpha-3 (P51812) (SMART)	OMIM:300075: Coffin-Lowry syndrome OMIM:303600: Mental retardation, X-linked nonspecific, type 19
  Protein kinase C gamma type (P05129) (SMART)	OMIM:176980: PROTEIN KINASE C, GAMMA; PRKCG
  Fibroblast growth factor receptor 3 (P22607) (SMART)	OMIM:134934: Achondroplasia OMIM:100800: Hypochondroplasia OMIM:146000: Thanatophoric dysplasia, types I and II OMIM:187600: Crouzon syndrome with acanthosis nigricans ; Muencke syndrome OMIM:602849: OMIM:600593: Craniosynostosis, Adelaide type
  Proto-oncogene tyrosine-protein kinase receptor Ret (P07949) (SMART)	OMIM:164761: Multiple endocrine neoplasia IIA OMIM:171400: Medullary thyroid carcinoma OMIM:155240: Multiple endocrine neoplasia IIB OMIM:162300: Hirschsprung disease OMIM:142623: OMIM:188550: Thyroid papillary carcinoma
  Serine/threonine-protein kinase 11 (Q15831) (SMART)	OMIM:602216: Peutz-Jeghers syndrome OMIM:175200:
  Cell division protein kinase 4 (P11802) (SMART)	OMIM:123829: Melanoma
  Angiopoietin-1 receptor (Q02763) (SMART)	OMIM:600221: Venous malformations, multiple cutaneous and mucosal OMIM:600195:
  Hepatocyte growth factor receptor (P08581) (SMART)	OMIM:164860: Renal cell carcinoma, papillary, familial and sporadic OMIM:605074: Hepatocellular carcinoma, childhood type OMIM:114550:
  Mast/stem cell growth factor receptor (P10721) (SMART)	OMIM:164920: Piebaldism ; Mast cell leukemia ; Mastocytosis with associated hematologic disorder ; Germ cell tumors OMIM:273300:

• Metabolism (metabolic pathways involving proteins which contain this domain)

• Click the image to view the interactive version of the map in iPath

  % proteins involved KEGG pathway ID Description 7.46 map04010 MAPK signaling pathway 3.88 map04912 GnRH signaling pathway 3.73 map04012 ErbB signaling pathway 3.58 map04910 Insulin signaling pathway 3.55 map04914 Progesterone-mediated oocyte maturation 3.54 map04510 Focal adhesion 2.72 map04720 Long-term potentiation 2.65 map04620 Toll-like receptor signaling pathway 2.62 map04310 Wnt signaling pathway 2.62 map04540 Gap junction 2.57 map04664 Fc epsilon RI signaling pathway 2.56 map04370 VEGF signaling pathway 2.53 map04150 mTOR signaling pathway 2.40 map04916 Melanogenesis 2.23 map04810 Regulation of actin cytoskeleton 2.10 map05214 Glioma 2.06 map04020 Calcium signaling pathway 2.04 map05223 Non-small cell lung cancer 2.01 map00632 Benzoate degradation via CoA ligation 2.01 map00562 Inositol phosphate metabolism 2.00 map05211 Renal cell carcinoma 1.97 map04530 Tight junction 1.92 map04360 Axon guidance 1.70 map05215 Prostate cancer 1.67 map05221 Acute myeloid leukemia 1.55 map04110 Cell cycle 1.52 map05212 Pancreatic cancer 1.51 map05213 Endometrial cancer 1.51 map04650 Natural killer cell mediated cytotoxicity 1.48 map05210 Colorectal cancer 1.48 map04730 Long-term depression 1.46 map05120 Epithelial cell signaling in Helicobacter pylori infection 1.42 map04670 Leukocyte transendothelial migration 1.39 map04920 Adipocytokine signaling pathway 1.36 map05220 Chronic myeloid leukemia 1.35 map04660 T cell receptor signaling pathway 1.29 map05218 Melanoma 1.24 map04740 Olfactory transduction 1.18 map05219 Bladder cancer 1.02 map04210 Apoptosis 1.01 map04520 Adherens junction 1.01 map04350 TGF-beta signaling pathway 0.92 map04340 Hedgehog signaling pathway 0.87 map04115 p53 signaling pathway 0.81 map04111 Cell cycle - yeast 0.80 map05216 Thyroid cancer 0.77 map04930 Type II diabetes mellitus 0.70 map04320 Dorso-ventral axis formation 0.68 map05222 Small cell lung cancer 0.65 map04140 Regulation of autophagy 0.61 map04742 Taste transduction 0.59 map04662 B cell receptor signaling pathway 0.46 map04630 Jak-STAT signaling pathway 0.43 map04070 Phosphatidylinositol signaling system 0.31 map05217 Basal cell carcinoma 0.19 map03320 PPAR signaling pathway 0.18 map05010 Alzheimer's disease 0.09 map04120 Ubiquitin mediated proteolysis 0.03 map00540 Lipopolysaccharide biosynthesis This information is based on mapping of SMART genomic protein database to KEGG orthologous groups. Percentage points are related to the number of proteins with S_TKc domain which could be assigned to a KEGG orthologous group, and not all proteins containing S_TKc domain. Please note that proteins can be included in multiple pathways, ie. the numbers above will not always add up to 100%.

• Structure (3D structures containing this domain)

• 3D Structures of S_TKc domains in PDB

  PDB code	Main view	Title
  1a06		Calmodulin-dependent protein kinase from rat
  1a9u		The complex structure of the map kinase p38/sb203580
  1apm		2.0 angstrom refined crystal structure of the catalytic subunit of camp-dependent protein kinase complexed with a peptide inhibitor and detergent
  1aq1		Human cyclin dependent kinase 2 complexed with the inhibitor staurosporine
  1atp		2.2 angstrom refined crystal structure of the catalytic subunit of camp-dependent protein kinase complexed with mnatp and a peptide inhibitor
  1b38		Human cyclin-dependent kinase 2
  1b39		Human cyclin-dependent kinase 2 phosphorylated on thr 160
  1bi7		Mechanism of g1 cyclin dependent kinase inhibition from the structure of the cdk6-p16ink4a tumor suppressor complex
  1bi8		Mechanism of g1 cyclin dependent kinase inhibition from the structures cdk6-p19ink4d inhibitor complex
  1bkx		A binary complex of the catalytic subunit of camp-dependent protein kinase and adenosine further defines conformational flexibility
  1bl6		The complex structure of the map kinase p38/sb216995
  1bl7		The complex structure of the map kinase p38/sb220025
  1blx		P19ink4d/cdk6 complex
  1bmk		The complex structure of the map kinase p38/sb218655
  1buh		Crystal structure of the human cdk2 kinase complex with cell cycle-regulatory protein ckshs1
  1bx6		Crystal structure of the potent natural product inhibitor balanol in complex with the catalytic subunit of camp- dependent protein kinase
  1cdk		Camp-dependent protein kinase catalytic subunit (e.c.2.7.1.37) (protein kinase a) complexed with protein kinase inhibitor peptide fragment 5-24 (pki(5-24) isoelectric variant ca) and mn2+ adenylyl imidodiphosphate (mnamp-pnp) at ph 5.6 and 7c and 4c
  1ckp		Human cyclin dependent kinase 2 complexed with the inhibitor purvalanol b
  1cm8		Phosphorylated map kinase p38-gamma
  1cmk		Crystal structures of the myristylated catalytic subunit of camp-dependent protein kinase reveal open and closed conformations
  1ctp		Structure of the mammalian catalytic subunit of camp- dependent protein kinase and an inhibitor peptide displays an open conformation
  1daw		Crystal structure of a binary complex of protein kinase ck2 (alpha-subunit) and mg-amppnp
  1day		Crystal structure of a binary complex of protein kinase ck2 (alpha-subunit) and mg-gmppnp
  1di8		The structure of cyclin-dependent kinase 2 (cdk2) in complex with 4-[3-hydroxyanilino]-6,7-dimethoxyquinazoline
  1di9		The structure of p38 mitogen-activated protein kinase in complex with 4-[3-methylsulfanylanilino]-6,7- dimethoxyquinazoline
  1dm2		Human cyclin-dependent kinase 2 complexed with the inhibitor hymenialdisine
  1ds5		Dimeric crystal structure of the alpha subunit in complex with two beta peptides mimicking the architecture of the tetrameric protein kinase ck2 holoenzyme.
  1e1v		Human cyclin dependent kinase 2 complexed with the inhibitor nu2058
  1e1x		Human cyclin dependent kinase 2 complexed with the inhibitor nu6027
  1e9h		Thr 160 phosphorylated cdk2 - human cyclin a3 complex with the inhibitor indirubin-5-sulphonate bound
  1erk		Structure of signal-regulated kinase
  1f0q		Crystal structure of the alpha subunit of protein kinase ck2 in complex with the nucleotide competitive inhibitor emodin
  1f3m		Crystal structure of human serine/threonine kinase pak1
  1f5q		Crystal structure of murine gamma herpesvirus cyclin complexed to human cyclin dependent kinase 2
  1fin		Cyclin a-cyclin-dependent kinase 2 complex
  1fmo		Crystal structure of a polyhistidine-tagged recombinant catalytic subunit of camp-dependent protein kinase complexed with the peptide inhibitor pki(5-24) and adenosine
  1fot		Structure of the unliganded camp-dependent protein kinase catalytic subunit from saccharomyces cerevisiae
  1fq1		Crystal structure of kinase associated phosphatase (kap) in complex with phospho-cdk2
  1fvt		The structure of cyclin-dependent kinase 2 (cdk2) in complex with an oxindole inhibitor
  1fvv		The structure of cdk2/cyclin a in complex with an oxindole inhibitor
  1g3n		Structure of a p18(ink4c)-cdk6-k-cyclin ternary complex
  1g5s		Crystal structure of human cyclin dependent kinase 2 (cdk2) in complex with the inhibitor h717
  1gih		Human cyclin dependent kinase 2 complexed with the cdk4 inhibitor
  1gii		Human cyclin dependent kinase 2 complexed with the cdk4 inhibitor
  1gij		Human cyclin dependent kinase 2 complexed with the cdk4 inhibitor
  1gng		Glycogen synthase kinase-3 beta (gsk3) complex with frattide peptide
  1gol		Coordinates of rat map kinase erk2 with an arginine mutation at position 52
  1gy3		Pcdk2/cyclin a in complex with mgadp, nitrate and peptide substrate
  1gz8		Human cyclin dependent kinase 2 complexed with the inhibitor 2-amino-6-(3'-methyl-2'-oxo)butoxypurine
  1gzk		Molecular mechanism for the regulation of protein kinase b/ akt by hydrophobic motif phosphorylation
  1gzn		Structure of pkb kinase domain
  1gzo		Structure of protein kinase b unphosphorylated
  1h00		Cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor
  1h01		Cdk2 in complex with a disubstituted 2, 4-bis anilino pyrimidine cdk4 inhibitor
  1h07		Cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor
  1h08		Cdk2 in complex with a disubstituted 2, 4-bis anilino pyrimidine cdk4 inhibitor
  1h0v		Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-amino-6-[(r)-pyrrolidino-5'-yl]methoxypurine
  1h0w		Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-amino-6-[cyclohex-3-enyl]methoxypurine
  1h1p		Structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu2058
  1h1q		Structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6094
  1h1r		Structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6086
  1h1s		Structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6102
  1h1w		High resolution crystal structure of the human pdk1 catalytic domain
  1h24		Cdk2/cyclin a in complex with a 9 residue recruitment peptide from e2f
  1h25		Cdk2/cyclin a in complex with an 11-residue recruitment peptide from retinoblastoma-associated protein
  1h26		Cdk2/cyclin a in complex with an 11-residue recruitment peptide from p53
  1h27		Cdk2/cyclin a in complex with an 11-residue recruitment peptide from p27
  1h28		Cdk2/cyclin a in complex with an 11-residue recruitment peptide from p107
  1h4l		Structure and regulation of the cdk5-p25(nck5a) complex
  1h8f		Glycogen synthase kinase 3 beta.
  1hck		Human cyclin-dependent kinase 2
  1hcl		Human cyclin-dependent kinase 2
  1how		The x-ray crystal structure of sky1p, an sr protein kinase in yeast
  1i09		Structure of glycogen synthase kinase-3 (gsk3b)
  1ia8		The 1.7 a crystal structure of human cell cycle checkpoint kinase chk1
  1ian		Human p38 map kinase inhibitor complex
  1ig1		1.8a x-ray structure of ternary complex of a catalytic domain of death-associated protein kinase with atp analogue and mn.
  1j1b		Binary complex structure of human tau protein kinase i with amppnp
  1j1c		Binary complex structure of human tau protein kinase i with adp
  1j3h		Crystal structure of apoenzyme camp-dependent protein kinase catalytic subunit
  1j91		Crystal structure of z. mays ck2 kinase alpha subunit in complex with the atp-competitive inhibitor 4,5,6,7- tetrabromobenzotriazole
  1jam		Crystal structure of apo-form of z. mays ck2 protein kinase alpha subunit
  1jbp		Crystal structure of the catalytic subunit of camp- dependent protein kinase complexed with a substrate peptide, adp and detergent
  1jkk		2.4a x-ray structure of ternary complex of a catalytic domain of death-associated protein kinase with atp analogue and mg.
  1jkl		1.6a x-ray structure of binary complex of a catalytic domain of death-associated protein kinase with atp analogue
  1jks		1.5a x-ray structure of apo form of a catalytic domain of death-associated protein kinase
  1jkt		Tetragonal crystal form of a catalytic domain of death- associated protein kinase
  1jlu		Crystal structure of the catalytic subunit of camp- dependent protein kinase complexed with a phosphorylated substrate peptide and detergent
  1jnk		The c-jun n-terminal kinase (jnk3s) complexed with mgamp-pnp
  1jow		Crystal structure of a complex of human cdk6 and a viral cyclin
  1jst		Phosphorylated cyclin-dependent kinase-2 bound to cyclin a
  1jsu		P27(kip1)/cyclin a/cdk2 complex
  1jsv		The structure of cyclin-dependent kinase 2 (cdk2) in complex with 4-[(6-amino-4-pyrimidinyl) amino]benzenesulfonamide
  1jvp		Crystal structure of human cdk2 (unphosphorylated) in complex with pkf049-365
  1jwh		Crystal structure of human protein kinase ck2 holoenzyme
  1ke5		Cdk2 complexed with n-methyl-4-{[(2-oxo-1,2-dihydro-3h- indol-3-ylidene)methyl]amino}benzenesulfonamide
  1ke6		Cyclin-dependent kinase 2 (cdk2) complexed with n-methyl-{4- [2-(7-oxo-6,7-dihydro-8h-[1,3]thiazolo[5,4-e]indol-8- ylidene)hydrazino]phenyl}methanesulfonamide
  1ke7		Cyclin-dependent kinase 2 (cdk2) complexed with 3-{[(2,2- dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5- (1,3-oxazol-5-yl)-1,3-dihydro-2h-indol-2-one
  1ke8		Cyclin-dependent kinase 2 (cdk2) complexed with 4-{[(2-oxo- 1,2-dihydro-3h-indol-3-ylidene)methyl]amino}-n-(1,3- thiazol-2-yl)benzenesulfonamide
  1ke9		Cyclin-dependent kinase 2 (cdk2) complexed with 3-{[4- ({[amino(imino)methyl]aminosulfonyl)anilino]methylene}-2- oxo-2,3-dihydro-1h-indole
  1koa		Twitchin kinase fragment (c.elegans), autoregulated protein kinase and immunoglobulin domains
  1kob		Twitchin kinase fragment (aplysia), autoregulated protein kinase domain
  1kv1		P38 map kinase in complex with inhibitor 1
  1kv2		Human p38 map kinase in complex with birb 796
  1kwp		Crystal structure of mapkap2
  1l3r		Crystal structure of a transition state mimic of the catalytic subunit of camp-dependent protein kinase
  1lew		Crystal structure of map kinase p38 complexed to the docking site on its nuclear substrate mef2a
  1lez		Crystal structure of map kinase p38 complexed to the docking site on its activator mkk3b
  1lp4		Crystal structure of a binary complex of the catalytic subunit of protein kinase ck2 with mg-amppnp
  1lpu		Low temperature crystal structure of the apo-form of the catalytic subunit of protein kinase ck2 from zea mays
  1lr4		Room temperature crystal structure of the apo-form of the catalytic subunit of protein kinase ck2 from zea mays
  1m2p		Crystal structure of 1,8-di-hydroxy-4-nitro- anthraquinone/ck2 kinase complex
  1m2q		Crystal structure of 1,8-di-hydroxy-4-nitro-xanten-9- one/ck2 kinase complex
  1m2r		Crystal structure of 5,8-di-amino-1,4-di-hydroxy- anthraquinone/ck2 kinase complex
  1m7q		Crystal structure of p38 map kinase in complex with a dihydroquinazolinone inhibitor
  1mq4		Crystal structure of aurora-a protein kinase
  1mru		Intracellular ser/thr protein kinase domain of mycobacterium tuberculosis pknb.
  1mrv		Crystal structure of an inactive akt2 kinase domain
  1mry		Crystal structure of an inactive akt2 kinase domain
  1muo		Crystal structure of aurora-2, an oncogenic serine- threonine kinase
  1na7		Crystal structure of the catalytic subunit of human protein kinase ck2
  1nvq		The complex structure of checkpoint kinase chk1/ucn-01
  1nvr		The complex structure of checkpoint kinase chk1/staurosporine
  1nvs		The complex structure of checkpoint kinase chk1/sb218078
  1nxk		Crystal structure of staurosporine bound to map kap kinase 2
  1ny3		Crystal structure of adp bound to map kap kinase 2
  1o6k		Structure of activated form of pkb kinase domain s474d with gsk3 peptide and amp-pnp
  1o6l		Crystal structure of an activated akt/protein kinase b (pkb-pif chimera) ternary complex with amp-pnp and gsk3 peptide
  1o6y		Catalytic domain of pknb kinase from mycobacterium tuberculosis
  1o9u		Glycogen synthase kinase 3 beta complexed with axin peptide
  1ob3		Structure of p. falciparum pfpk5
  1ogu		Structure of human thr160-phospho cdk2/cyclin a complexed with a 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitor
  1oi9		Structure of human thr160-phospho cdk2/cyclin a complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor
  1oiq		Imidazopyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation
  1oir		Imidazopyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation
  1oit		Imidazopyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation
  1oiu		Structure of human thr160-phospho cdk2/cyclin a complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor
  1oiy		Structure of human thr160-phospho cdk2/cyclin a complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor
  1okv		Cyclin a binding groove inhibitor h-arg-arg-leu-ile-phe-nh2
  1okw		Cyclin a binding groove inhibitor ac-arg-arg-leu-asn- (m-cl-phe)-nh2
  1oky		Structure of human pdk1 kinase domain in complex with staurosporine
  1okz		Structure of human pdk1 kinase domain in complex with ucn-01
  1ol1		Cyclin a binding groove inhibitor h-cit-cit-leu-ile- (p-f-phe)-nh2
  1ol2		Cyclin a binding groove inhibitor h-arg-arg-leu-asn- (p-f-phe)-nh2
  1ol5		Structure of aurora-a 122-403, phosphorylated on thr287, thr288 and bound to tpx2 1-43
  1ol6		Structure of unphosphorylated d274n mutant of aurora-a
  1ol7		Structure of human aurora-a 122-403 phosphorylated on thr287, thr288
  1om1		Crystal structure of maize ck2 alpha in complex with iqa
  1omw		Crystal structure of the complex between g protein-coupled receptor kinase 2 and heterotrimeric g protein beta 1 and gamma 2 subunits
  1ouk		The structure of p38 alpha in complex with a pyridinylimidazole inhibitor
  1ouy		The structure of p38 alpha in complex with a dihydropyrido- pyrimidine inhibitor
  1ove		The structure of p38 alpha in complex with a dihydroquinolinone
  1oz1		P38 mitogen-activated kinase in complex with 4-azaindole inhibitor
  1p2a		The structure of cyclin dependent kinase 2 (ckd2) with a trisubstituted naphthostyril inhibitor
  1p38		The structure of the map kinase p38 at 2.1 angstoms resolution
  1p4f		Death associated protein kinase catalytic domain with bound inhibitor fragment
  1p5e		The strucure of phospho-cdk2/cyclin a in complex with the inhibitor 4,5,6,7-tetrabromobenzotriazole (tbs)
  1pf8		Crystal structure of human cyclin-dependent kinase 2 complexed with a nucleoside inhibitor
  1phk		Two structures of the catalytic domain of phosphorylase, kinase: an active protein kinase complexed with nucleotide, substrate-analogue and product
  1pjk		Crystal structure of a c-terminal deletion mutant of human protein kinase ck2 catalytic subunit
  1pkd		The crystal structure of ucn-01 in complex with phospho- cdk2/cyclin a
  1pme		Structure of penta mutant human erk2 map kinase complexed with a specific inhibitor of human p38 map kinase
  1pmn		Crystal structure of jnk3 in complex with an imidazole- pyrimidine inhibitor
  1pmq		The structure of jnk3 in complex with an imidazole- pyrimidine inhibitor
  1pmu		The crystal structure of jnk3 in complex with a phenantroline inhibitor
  1pmv		The structure of jnk3 in complex with a dihydroanthrapyrazole inhibitor
  1pw2		Apo structure of human cyclin-dependent kinase 2
  1pxi		Human cyclin dependent kinase 2 complexed with the inhibitor 4-(2,5-dichloro-thiophen-3-yl)-pyrimidin-2- ylamine
  1pxj		Human cyclin dependent kinase 2 complexed with the inhibitor 4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-ylamine
  1pxk		Human cyclin dependent kinase 2 complexed with the inhibitor n-[4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-yl]- n'-hydroxyiminoformamide
  1pxl		Human cyclin dependent kinase 2 complexed with the inhibitor [4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]- (4-trifluoromethyl-phenyl)-amine
  1pxm		Human cyclin dependent kinase 2 complexed with the inhibitor 3-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2- ylamino]-phenol
  1pxn		Human cyclin dependent kinase 2 complexed with the inhibitor 4-[4-(4-methyl-2-methylamino-thiazol-5-yl)- pyrimidin-2-ylamino]-phenol
  1pxo		Human cyclin dependent kinase 2 complexed with the inhibitor [4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2- yl]-(3-nitro-phenyl)-amine
  1pxp		Human cyclin dependent kinase 2 complexed with the inhibitor n-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]- n',n'-dimethyl-benzene-1,4-diamine
  1pye		Crystal structure of cdk2 with inhibitor
  1pyx		Gsk-3 beta complexed with amp-pnp
  1q24		Pka double mutant model of pkb in complex with mgatp
  1q3d		Gsk-3 beta complexed with staurosporine
  1q3w		Gsk-3 beta complexed with alsterpaullone
  1q41		Gsk-3 beta complexed with indirubin-3'-monoxime
  1q4l		Gsk-3 beta complexed with inhibitor i-5
  1q5k		Crystal structure of glycogen synthase kinase 3 in complexed with inhibitor
  1q61		Pka triple mutant model of pkb
  1q62		Pka double mutant model of pkb
  1q8t		The catalytic subunit of camp-dependent protein kinase (pka) in complex with rho-kinase inhibitor y-27632
  1q8u		The catalytic subunit of camp-dependent protein kinase in complex with rho-kinase inhibitor h-1152p
  1q8w		The catalytic subunit of camp-dependent protein kinase in complex with rho-kinase inhibitor fasudil (ha-1077)
  1q8y		The structure of the yeast sr protein kinase, sky1p, with bound adp
  1q8z		The apoenzyme structure of the yeast sr protein kinase, sky1p
  1q97		The structure of the saccharomyces cerevisiae sr protein kinase, sky1p, with bound atp
  1q99		Crystal structure of the saccharomyces cerevisiae sr protein kinsae, sky1p, complexed with the non-hydrolyzable atp analogue, amp-pnp
  1ql6		The catalytic mechanism of phosphorylase kinase probed by mutational studies
  1qmz		Phosphorylated cdk2-cyclyin a-substrate peptide complex
  1r0e		Glycogen synthase kinase-3 beta in complex with 3-indolyl-4- arylmaleimide inhibitor
  1r39		The structure of p38alpha
  1r3c		The structure of p38alpha c162s mutant
  1r78		Cdk2 complex with a 4-alkynyl oxindole inhibitor
  1rdq		Hydrolysis of atp in the crystal of y204a mutant of camp- dependent protein kinase
  1re8		Crystal structure of camp-dependent protein kinase complexed with balanol analog 2
  1rej		Crystal structure of camp-dependent protein kinase complexed with balanol analog 1
  1rek		Crystal structure of camp-dependent protein kinase complexed with balanol analog 8
  1s9i		X-ray structure of the human mitogen-activated protein kinase kinase 2 (mek2)in a complex with ligand and mgatp
  1s9j		X-ray structure of the human mitogen-activated protein kinase kinase 1 (mek1) in a complex with ligand and mgatp
  1smh		Protein kinase a variant complex with completely ordered n- terminal helix
  1stc		Camp-dependent protein kinase, alpha-catalytic subunit in complex with staurosporine
  1sve		Crystal structure of protein kinase a in complex with azepane derivative 1
  1svg		Crystal structure of protein kinase a in complex with azepane derivative 4
  1svh		Crystal structure of protein kinase a in complex with azepane derivative 8
  1syk		Crystal structure of e230q mutant of camp-dependent protein kinase reveals unexpected apoenzyme conformation
  1szm		Dual binding mode of bisindolylmaleimide 2 to protein kinase a (pka)
  1tki		Autoinhibited serine kinase domain of the giant muscle protein titin
  1tvo		The structure of erk2 in complex with a small molecule inhibitor
  1u5q		Crystal structure of the tao2 kinase domain: activation and specifity of a ste20p map3k
  1u5r		Crystal structure of the tao2 kinase domain: activation and specifity of a ste20p map3k
  1ua2		Crystal structure of human cdk7
  1ukh		Structural basis for the selective inhibition of jnk1 by the scaffolding protein jip1 and sp600125
  1uki		Structural basis for the selective inhibition of jnk1 by the scaffolding protein jip1 and sp600125
  1ung		Structural mechanism for the inhibition of cdk5-p25 by roscovitine, aloisine and indirubin.
  1unh		Structural mechanism for the inhibition of cdk5-p25 by roscovitine, aloisine and indirubin.
  1unl		Structural mechanism for the inhibition of cd5-p25 from the roscovitine, aloisine and indirubin.
  1urc		Cyclin a binding groove inhibitor ace-arg-lys-leu- phe-gly
  1urw		Cdk2 in complex with an imidazo[1,2-b]pyridazine
  1uu3		Structure of human pdk1 kinase domain in complex with ly333531
  1uu7		Structure of human pdk1 kinase domain in complex with bim-2
  1uu8		Structure of human pdk1 kinase domain in complex with bim-1
  1uu9		Structure of human pdk1 kinase domain in complex with bim-3
  1uv5		Glycogen synthase kinase 3 beta complexed with 6-bromoindirubin-3'-oxime
  1uvr		Structure of human pdk1 kinase domain in complex with bim-8
  1v0b		Crystal structure of the t198a mutant of pfpk5
  1v0o		Structure of p. falciparum pfpk5-indirubin-5-sulphonate ligand complex
  1v0p		Structure of p. falciparum pfpk5-purvalanol b ligand complex
  1v1k		Cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor
  1veb		Crystal structure of protein kinase a in complex with azepane derivative 5
  1vyw		Structure of cdk2/cyclin a with pnu-292137
  1vyz		Structure of cdk2 complexed with pnu-181227
  1vzo		The structure of the n-terminal kinase domain of msk1 reveals a novel autoinhibitory conformation for a dual kinase protein
  1w0x		Crystals structure of human cdk2 in complex with the inhibitor olomoucine.
  1w7h		P38 kinase crystal structure in complex with small molecule inhibitor
  1w82		P38 kinase crystal structure in complex with small molecule inhibitor
  1w83		P38 kinase crystal structure in complex with small molecule inhibitor
  1w84		P38 kinase crystal structure in complex with small molecule inhibitor
  1w8c		Co-crystal structure of 6-cyclohexylmethoxy-8-isopropyl-9h- purin-2-ylamine and monomeric cdk2
  1w98		The structural basis of cdk2 activation by cyclin e
  1wbn		Fragment based p38 inhibitors
  1wbo		Fragment based p38 inhibitors
  1wbs		Identification of novel p38 alpha map kinase inhibitors using fragment-based lead generation.
  1wbt		Identification of novel p38 alpha map kinase inhibitors using fragment-based lead generation.
  1wbv		Identification of novel p38 alpha map kinase inhibitors using fragment-based lead generation.
  1wbw		Identification of novel p38 alpha map kinase inhibitors using fragment-based lead generation.
  1wcc		Screening for fragment binding by x-ray crystallography
  1wfc		Structure of apo, unphosphorylated, p38 mitogen activated protein kinase p38 (p38 map kinase) the mammalian homologue of the yeast hog1 protein
  1wmk		Human death-associated kinase drp-1, mutant s308d d40
  1wvw		Crystal structures of kinase domain of dap kinase in complex with small molecular inhibitors
  1wvx		Crystal structures of kinase domain of dap kinase in complex with small molecular inhibitors
  1wvy		Crystal structures of kinase domain of dap kinase in complex with small molecular inhibitors
  1wzy		Crystal structure of human erk2 complexed with a pyrazolopyridazine derivative
  1xh4		Crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants
  1xh5		Crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants
  1xh6		Crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants
  1xh7		Crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants
  1xh8		Crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants
  1xh9		Crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants
  1xha		Crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants
  1xjd		Crystal structure of pkc-theta complexed with staurosporine at 2a resolution
  1xo2		Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin
  1xqz		Crystal structure of hpim-1 kinase at 2.1 a resolution
  1xr1		Crystal structure of hpim-1 kinase in complex with amp-pnp at 2.1 a resolution
  1xws		Crystal structure of the human pim1 kinase domain
  1y8g		Catalytic and ubiqutin-associated domains of mark2/par-1: inactive double mutant with selenomethionine
  1y8y		Crystal structure of human cdk2 complexed with a pyrazolo[1, 5-a]pyrimidine inhibitor
  1y91		Crystal structure of human cdk2 complexed with a pyrazolo[1, 5-a]pyrimidine inhibitor
  1ydr		Structure of camp-dependent protein kinase, alpha-catalytic subunit in complex with h7 protein kinase inhibitor 1-(5- isoquinolinesulfonyl)-2-methylpiperazine
  1yds		Structure of camp-dependent protein kinase, alpha-catalytic subunit in complex with h8 protein kinase inhibitor [n-(2- methylamino)ethyl]-5-isoquinolinesulfonamide
  1ydt		Structure of camp-dependent protein kinase, alpha-catalytic subunit in complex with h89 protein kinase inhibitor n-[2- (4-bromocinnamylamino)ethyl]-5-isoquinoline
  1yhs		Crystal structure of pim-1 bound to staurosporine
  1yhv		Crystal structure of pak1 kinase domain with two point mutations (k299r, t423e)
  1yhw		Crystal structure of pak1 kinase domain with one point mutations (k299r)
  1yi3		Crystal structure of pim-1 bound to ly294002
  1yi4		Structure of pim-1 bound to adenosine
  1ykr		Crystal structure of cdk2 with an aminoimidazo pyridine inhibitor
  1ym7		G protein-coupled receptor kinase 2 (grk2)
  1yqj		Crystal structure of p38 alpha in complex with a selective pyridazine inhibitor
  1yrp		Catalytic domain of human zip kinase phosphorylated at thr265
  1yw2		Mutated mus musculus p38 kinase (mp38)
  1ywr		Crystal structure analysis of inactive p38 kinase domain in complex with a monocyclic pyrazolone inhibitor
  1ywv		Crystal structures of proto-oncogene kinase pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma
  1yxs		Crystal structure of kinase pim1 with p123m mutation
  1yxt		Crystal structure of kinase pim1 in complex with amppnp
  1yxu		Crystal structure of kinase pim1 in complex with amp
  1yxv		Crystal structure of kinase pim1 in complex with 3,4- dihydroxy-1-methylquinolin-2(1h)-one
  1yxx		Crystal structure of kinase pim1 in complex with (3e)-3-[(4- hydroxyphenyl)imino]-1h-indol-2(3h)-one
  1z57		Crystal structure of human clk1 in complex with 10z- hymenialdisine
  1z5m		Crystal structure of n1-[3-[[5-bromo-2-[[3-[(1- pyrrolidinylcarbonyl)amino]phenyl]amino]-4- pyrimidinyl]amino]propyl]-2,2-dimethylpropanediamide complexed with human pdk1
  1z9x		Human drp-1 kinase, w305s s308a d40 mutant, crystal form with 3 monomers in the asymmetric unit
  1zlt		Crystal structure of chk1 complexed with a hymenaldisine analog
  1zmu		Catalytic and ubiqutin-associated domains of mark2/par-1: wild type
  1zmv		Catalytic and ubiqutin-associated domains of mark2/par-1: k82r mutant
  1zmw		Catalytic and ubiqutin-associated domains of mark2/par-1: t208a/s212a inactive double mutant
  1zoe		Crystal structure of protein kinase ck2 in complex with tbb- derivatives inhibitors
  1zog		Crystal structure of protein kinase ck2 in complex with tbb- derivatives
  1zoh		Crystal structure of protein kinase ck2 in complex with tbb- derivatives inhibitors
  1zrz		Crystal structure of the catalytic domain of atypical protein kinase c-iota
  1zws		Crystal structure of the catalytic domain of human drp-1 kinase
  1zxe		Crystal structure of eif2alpha protein kinase gcn2: d835n inactivating mutant in apo form
  1zy4		Crystal structure of eif2alpha protein kinase gcn2: r794g hyperactivating mutant in apo form.
  1zy5		Crystal structure of eif2alpha protein kinase gcn2: r794g hyperactivating mutant complexed with amppnp.
  1zyc		Crystal structure of eif2alpha protein kinase gcn2: wild- type in apo form.
  1zyd		Crystal structure of eif2alpha protein kinase gcn2: wild- type complexed with atp.
  1zyj		Human p38 map kinase in complex with inhibitor 1a
  1zys		Co-crystal structure of checkpoint kinase chk1 with a pyrrolo-pyridine inhibitor
  1zz2		Two classes of p38alpha map kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes
  1zzl		Crystal structure of p38 with triazolopyridine
  2a0c		Human cdk2 in complex with olomoucine ii, a novel 2,6,9- trisubstituted purine cyclin-dependent kinase inhibitor
  2a27		Human drp-1 kinase, w305s s308a d40 mutant, crystal form with 8 monomers in the asymmetric unit
  2a2a		High-resolution crystallographic analysis of the autoinhibited conformation of a human death-associated protein kinase
  2a4l		Human cyclin-dependent kinase 2 in complex with roscovitine
  2ac3		Structure of human mnk2 kinase domain
  2ac5		Structure of human mnk2 kinase domain mutant d228g
  2acx		Crystal structure of g protein coupled receptor kinase 6 bound to amppnp
  2ayp		Crystal structure of chk1 with an indol inhibitor
  2b1p		Inhibitor complex of jnk3
  2b52		Human cyclin dependent kinase 2 (cdk2) complexed with dph-
  2b53		Human cyclin dependent kinase 2 (cdk2) complexed with din-
  2b54		Human cyclin dependent kinase 2 (ckd2)complexed with din-
  2b55		Human cyclin dependent kinase 2 (cdk2) complexed with indenopyraxole din-101312
  2b9f		Crystal structure of non-phosphorylated fus3
  2b9h		Crystal structure of fus3 with a docking motif from ste7
  2b9i		Crystal structure of fus3 with a docking motif from msg5
  2b9j		Crystal structure of fus3 with a docking motif from far1
  2baj		P38alpha bound to pyrazolourea
  2bak		P38alpha map kinase bound to mpaq
  2bal		P38alpha map kinase bound to pyrazoloamine
  2baq		P38alpha bound to ro3201195
  2bcj		Crystal structure of g protein-coupled receptor kinase 2 in complex with galpha-q and gbetagamma subunits
  2bdw		Crystal structure of the auto-inhibited kinase domain of calcium/calmodulin activated kinase ii
  2bfx		Mechanism of aurora-b activation by incenp and inhibition by hesperidin.
  2bfy		Complex of aurora-b with incenp and hesperidin.
  2bhe		Human cyclin dependent protein kinase 2 in complex with the inhibitor 5-bromo-indirubine
  2bhh		Human cyclin dependent protein kinase 2 in complex with the inhibitor 4-hydroxypiperindinesulfonyl-indirubine
  2bik		Human pim1 phosphorylated on ser261
  2bil		The human protein kinase pim1 in complex with its consensus peptide pimtide
  2biy		Structure of pdk1-s241a mutant kinase domain
  2bkz		Structure of cdk2-cyclin a with pha-404611
  2bmc		Aurora-2 t287d t288d complexed with pha-680632
  2bpm		Structure of cdk2-cyclin a with pha-630529
  2br1		Structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity
  2brb		Structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity
  2brg		Structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity
  2brh		Structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity
  2brm		Structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity
  2brn		Structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity
  2bro		Structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity
  2btr		Structure of cdk2 complexed with pnu-198873
  2bts		Structure of cdk2 complexed with pnu-230032
  2bva		Crystal structure of the human p21-activated kinase 4
  2bzh		Crystal structure of the human pim1 in complex with a ruthenium organometallic ligand ru1
  2bzi		Crystal structure of the human pim1 in complex with a ruthenium organometallic ligand ru2
  2bzj		Crystal structure of the human pim1 in complex with a ruthenium organometallic ligand ru3
  2bzk		Crystal structure of the human pim1 in complex with amppnp and pimtide
  2c1a		Structure of camp-dependent protein kinase complexed with isoquinoline-5-sulfonic acid (2-(2-(4-chlorobenzyloxy) ethylamino)ethyl)amide
  2c1b		Structure of camp-dependent protein kinase complexed with ( 4r,2s)-5'-(4-(4-chlorobenzyloxy)pyrrolidin-2- ylmethanesulfonyl)isoquinoline
  2c30		Crystal structure of the human p21-activated kinase 6
  2c3i		Crystal structure of human pim1 in complex with imidazopyridazin i
  2c3j		Identification of a buried pocket for potent and selective inhibition of chk1: prediction and verification
  2c3k		Identification of a buried pocket for potent and selective inhibition of chk1: prediction and verification
  2c3l		Identification of a buried pocket for potent and selective inhibition of chk1: prediction and verification
  2c4g		Structure of cdk2-cyclin a with pha-533514
  2c5n		Differential binding of inhibitors to active and inactive cdk2 provides insights for drug design
  2c5o		Differential binding of inhibitors to active and inactive cdk2 provides insights for drug design
  2c5v		Differential binding of inhibitors to active and inactive cdk2 provides insights for drug design
  2c5x		Differential binding of inhibitors to active and inactive cdk2 provides insights for drug design
  2c5y		Differential binding of inhibitors to active and inactive cdk2 provides insights for drug design
  2c68		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
  2c69		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
  2c6d		Aurora a kinase activated mutant (t287d) in complex with adpnp
  2c6e		Aurora a kinase activated mutant (t287d) in complex with a 5-aminopyrimidinyl quinazoline inhibitor
  2c6i		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
  2c6k		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
  2c6l		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
  2c6m		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
  2c6o		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
  2c6t		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
  2cch		The crystal structure of cdk2 cyclin a in complex with a substrate peptide derived from cdc modified with a gamma- linked atp analogue
  2cci		Crystal structure of phospho-cdk2 cyclin a in complex with a peptide containing both the substrate and recruitment sites of cdc6
  2cdz		Crystal structure of the human p21-activated kinase 4 in complex with cgp74514a
  2cgu		Identification of chemically diverse chk1 inhibitors by receptor-based virtual screening
  2cgv		Identification of chemically diverse chk1 inhibitors by receptor-based virtual screening
  2cgw		Identification of chemically diverse chk1 inhibitors by receptor-based virtual screening
  2cgx		Identification of chemically diverse chk1 inhibitors by receptor-based virtual screening
  2cjm		Mechanism of cdk inhibition by active site phosphorylation: cdk2 y15p t160p in complex with cyclin a structure
  2cke		Human death-associated drp-1 kinase in complex with inhibitor
  2clq		Structure of mitogen-activated protein kinase kinase kinase
  2clx		4-arylazo-3,5-diamino-1h-pyrazole cdk inhibitors: sar study, crystal structure in complex with cdk2, selectivity, and cellular effects
  2cn5		Crystal structure of human chk2 in complex with adp
  2cn8		Crystal structure of human chk2 in complex with debromohymenialdisine
  2cpk		Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase
  2ds1		Human cyclin dependent kinase 2 complexed with the cdk4 inhibitor
  2duv		Structure of cdk2 with a 3-hydroxychromones
  2dwb		Aurora-a kinase complexed with amppnp
  2dyl		Crystal structure of human mitogen-activated protein kinase kinase 7 activated mutant (s287d, t291d)
  2e14		The structure of erk2 in complex with fr148083
  2e9n		Structure of h-chk1 complexed with a767085
  2e9o		Structure of h-chk1 complexed with aa582939
  2e9p		Structure of h-chk1 complexed with a771129
  2e9u		Structure of h-chk1 complexed with a780125
  2e9v		Structure of h-chk1 complexed with a859017
  2erk		Phosphorylated map kinase erk2
  2erz		Crystal structure of c-amp dependent kinase (pka) bound to hydroxyfasudil
  2esm		Crystal structure of rock 1 bound to fasudil
  2etk		Crystal structure of rock 1 bound to hydroxyfasudil
  2etr		Crystal structure of rock i bound to y-27632
  2eu9		Crystal structure of clk3
  2euf		X-ray structure of human cdk6-vcyclin in complex with the inhibitor pd0332991
  2ewa		Dual binding mode of pyridinylimidazole to map kinase p38
  2exc		Inhibitor complex of jnk3
  2exe		Crystal structure of the phosphorylated clk3
  2exm		Human cdk2 in complex with isopentenyladenine
  2f2c		X-ray structure of human cdk6-vcyclinwith the inhibitor aminopurvalanol
  2f2u		Crystal structure of the rho-kinase kinase domain
  2f49		Crystal structure of fus3 in complex with a ste5 peptide
  2f57		Crystal structure of the human p21-activated kinase 5
  2f7e		Pka complexed with (s)-2-(1h-indol-3-yl)-1-(5-isoquinolin-6- yl-pyridin-3-yloxymethyl-etylamine
  2f7x		Protein kinase a bound to (s)-2-(1h-indol-3-yl)-1-[5-((e)-2- pyridin-4-yl-vinyl)-pyridin-3-yloxymethyl]-ethylamine
  2f7z		Protein kinase a bound to (r)-1-(1h-indol-3-ylmethyl)-2-(2- pyridin-4-yl-[1,7]naphtyridin-5-yloxy)-ehylamine
  2f9g		Crystal structure of fus3 phosphorylated on tyr182
  2fa2		Crystal structure of fus3 without a peptide from ste5
  2fh9		Structure and dimerization of the kinase domain from yeast snf1
  2fsl		Mitogen activated protein kinase p38alpha (d176a+f327s) activating mutant form-a
  2fsm		Mitogen activated protein kinase p38alpha (d176a+f327s) activating mutant form-b
  2fso		Mitogen activated protein kinase p38alpha (d176a) activating mutant
  2fst		Mitogen activated protein kinase p38alpha (d176a+f327l) activating mutant
  2fum		Catalytic domain of protein kinase pknb from mycobacterium tuberculosis in complex with mitoxantrone
  2fvd		Cyclin dependent kinase 2 (cdk2) with diaminopyrimidine inhibitor
  2fys		Crystal structure of erk2 complex with kim peptide derived from mkp3
  2g01		Pyrazoloquinolones as novel, selective jnk1 inhibitors
  2g9x		Structure of thr 160 phosphorylated cdk2/cyclin a in complex with the inhibitor nu6271
  2gcd		Tao2 kinase domain-staurosporine structure
  2gdo		4-(aminoalkylamino)-3-benzimidazole-quinolinones as potent chk1 inhibitors
  2gfc		Camp-dependent protein kinase pka catalytic subunit with pki-5-24
  2gfs		P38 kinase crystal structure in complex with ro3201195
  2ghg		H-chk1 complexed with a431994
  2ghl		Mutant mus musculus p38 kinase domain in complex with inhibitor pg-874743
  2ghm		Mutated map kinase p38 (mus musculus) in complex with inhbitor pg-895449
  2gmx		Selective aminopyridine-based c-jun n-terminal kinase inhibitors with cellular activity
  2gnf		Protein kinase a fivefold mutant model of rho-kinase with y-
  2gng		Protein kinase a fivefold mutant model of rho-kinase
  2gnh		Pka five fold mutant model of rho-kinase with h1152p
  2gni		Pka fivefold mutant model of rho-kinase with inhibitor fasudil (ha1077)
  2gnj		Pka three fold mutant model of rho-kinase with y-27632
  2gnl		Pka threefold mutant model of rho-kinase with inhibitor h- 1152p
  2gph		Docking motif interactions in the map kinase erk2
  2gtm		Mutated mouse p38 map kinase domain in complex with inhibitor pg-892579
  2gtn		Mutated map kinase p38 (mus musculus) in complex with inhbitor pg-951717
  2gu8		Discovery of 2-pyrimidyl-5-amidothiophenes as novel and potent inhibitors for akt: synthesis and sar studies
  2h6d		Protein kinase domain of the human 5'-amp-activated protein kinase catalytic subunit alpha-2 (ampk alpha-2 chain)
  2h96		Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-jun nh2-terminal kinase inhibitors
  2h9v		Structural basis for induced-fit binding of rho-kinase to the inhibitor y27632
  2hak		Catalytic and ubiqutin-associated domains of mark1/par-1
  2hog		Crystal structure of chek1 in complex with inhibitor 20
  2hw6		Crystal structure of mnk1 catalytic domain
  2hw7		Crystal structure of mnk2-d228g in complex with staurosporine
  2hxl		Crystal structure of chek1 in complex with inhibitor 1
  2hxq		Crystal structure of chek1 in complex with inhibitor 2
  2hy0		Crystal structure of chek1 in complex with inhibitor 22
  2hy8		Pak1 complex with st2001
  2i0e		Structure of catalytic domain of human protein kinase c beta ii complexed with a bisindolylmaleimide inhibitor
  2i0h		The structure of p38alpha in complex with an arylpyridazinone
  2i40		Cdk2/cyclin a complexed with a thiophene carboxamide inhibitor
  2i6l		Crystal structure of human mitogen activated protein kinase (mapk6)
  2iw6		Structure of human thr160-phospho cdk2-cyclin a complexed with a bisanilinopyrimidine inhibitor
  2iw8		Structure of human thr160-phospho cdk2-cyclin a f82h-l83v- h84d mutant with an o6-cyclohexylmethylguanine inhibitor
  2iw9		Structure of human thr160-phospho cdk2-cyclin a complexed with a bisanilinopyrimidine inhibitor
  2iwi		Crystal structure of the human pim2 in complex with a ruthenium organometallic ligand ru1
  2j0i		Crystal structure of the human p21-activated kinase 4
  2j2i		Crystal structure of the humab pim1 in complex with ly333531
  2j4z		Structure of aurora-2 in complex with pha-680626
  2j50		Structure of aurora-2 in complex with pha-739358
  2j51		Crystal structure of human ste20-like kinase bound to 5- amino-3-((4-(aminosulfonyl)phenyl)amino)-n-(2,6- difluorophenyl)-1h-1,2,4-triazole-1-carbothioamide
  2j7t		Crystal structure of human serine threonine kinase-10 bound to su11274
  2j90		Crystal structure of human zip kinase in complex with a tetracyclic pyridone inhibitor (pyridone 6)
  2j9m		Crystal structure of cdk2 in complex with macrocyclic aminopyrimidine
  2jam		Crystal structure of human calmodulin-dependent protein kinase i g
  2jav		Human kinase with pyrrole-indolinone ligand
  2jbo		Protein kinase mk2 in complex with an inhibitor (crystal form-1, soaking)
  2jbp		Protein kinase mk2 in complex with an inhibitor (crystal form-2, co-crystallization)
  2jc6		Crystal structure of human calmodulin-dependent protein kinase 1d
  2jd5		Sky1p bound to npl3p-derived substrate peptide
  2jdo		Structure of pkb-beta (akt2) complexed with isoquinoline-5- sulfonic acid (2-(2-(4-chlorobenzyloxy) ethylamino)ethyl) amide
  2jdr		Structure of pkb-beta (akt2) complexed with the inhibitor a-
  2jds		Structure of camp-dependent protein kinase complexed with a-
  2jdt		Structure of pka-pkb chimera complexed with isoquinoline-5- sulfonic acid (2-(2-(4-chlorobenzyloxy) ethylamino)ethyl) amide
  2jdv		Structure of pka-pkb chimera complexed with a-443654
  2jed		The crystal structure of the kinase domain of the protein kinase c theta in complex with nvp-xaa228 at 2.32a resolution.
  2jfl		Crystal structure of human ste20-like kinase ( diphosphorylated form) bound to 5- amino-3-((4-( aminosulfonyl)phenyl)amino)-n-(2,6- difluorophenyl)-1h-1,2, 4-triazole-1-carbothioamide
  2jfm		Crystal structure of human ste20-like kinase (unliganded form)
  2jgz		Crystal structure of phospho-cdk2 in complex with cyclin b
  2jld		Extremely tight binding of ruthenium complex to glycogen synthase kinase 3
  2no3		Novel 4-anilinopyrimidines as potent jnk1 inhibitors
  2np8		Structural basis for the inhibition of aurora a kinase by a novel class of high affinity disubstituted pyrimidine inhibitors
  2npq		A novel lipid binding site in the p38 alpha map kinase
  2o0u		Crystal structure of human jnk3 complexed with n-{3-cyano-6- [3-(1-piperidinyl)propanoyl]-4,5,6,7-tetrahydrothieno[2,3- c]pyridin-2-yl}-1-naphthalenecarboxamide
  2o2u		Crystal structure of human jnk3 complexed with n-(3-cyano-4, 5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide
  2o3p		Crystal structure of pim1 with quercetin
  2o5k		Crystal structure of gsk3beta in complex with a benzoimidazol inhibitor
  2o63		Crystal structure of pim1 with myricetin
  2o64		Crystal structure of pim1 with quercetagetin
  2o65		Crystal structure of pim1 with pentahydroxyflavone
  2obj		Crystal structure of human pim-1 kinase in complex with inhibitor
  2oh0		Crystal structure of protein kinase a in complex with pyridine-pyrazolopyridine based inhibitors
  2oi4		Crystal structure of human pim1 in complex with fluorinated ruthenium pyridocarbazole
  2ojf		Crystal structure of protein kinase a in complex with pyridine-pyrazolopyridine based inhibitors
  2ojg		Crystal structure of erk2 in complex with n,n-dimethyl-4-(4- phenyl-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide
  2oji		Crystal structure of erk2 in complex with n-benzyl-4-(4-(3- chlorophenyl)-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide
  2ojj		Crystal structure of erk2 in complex with (s)-n-(1-(3- chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(3- chlorophenyl)-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide
  2ok1		Crystal structure of jnk3 bound to n-benzyl-4-(4-(3- chlorophenyl)-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide
  2okr		Crystal structure of the p38a-mapkap kinase 2 heterodimer
  2onl		Crystal structure of the p38a-mapkap kinase 2 heterodimer
  2ou7		Structure of the catalytic domain of human polo-like kinase
  2ow3		Glycogen synthase kinase-3 beta in complex with bis- (indole)maleimide pyridinophane inhibitor
  2owb		Structure of the catalytic domain of human polo-like kinase
  2oxd		Protein kinase ck2 in complex with tetrabromobenzoimidazole k17, k22 and k32 inhibitors
  2oxx		Protein kinase ck2 in complex with tetrabromobenzoimidazole derivatives k17, k22 and k32
  2oxy		Protein kinase ck2 in complex with tetrabromobenzoimidazole derivatives k17, k22 and k32
  2oza		Structure of p38alpha complex
  2p33		Synthesis and sar of aminopyrimidines as novel c-jun n- terminal kinase (jnk) inhibitors
  2p3g		Crystal structure of a pyrrolopyridine inhibitor bound to mapkap kinase-2
  2p55		X-ray structure of the human mitogen-activated protein kinase kinase 1 (mek1) in a complex with ligand and mgatp
  2pe0		Crystal structure of human phosphoinositide-dependent protein kinase 1 (pdk1) 5-hydroxy-3-[1-(1h-pyrrol-2-yl)- eth-(z)-ylidene]-1,3-dihydro-indol-2-one complex
  2pe1		Crystal structure of human phosphoinositide-dependent protein kinase 1 (pdk1) {2-oxo-3-[1-(1h-pyrrol-2-yl)-eth- (z)-ylidene]-2,3-dihydro-1h-indol-5-yl}-urea {bx-517} complex
  2pe2		Crystal structure of human phosphoinositide-dependent protein kinase 1 (pdk1) 3-{5-[2-oxo-5-ureido-1,2-dihydro- indol-(3z)-ylidenemethyl]-1h-pyrrol-3-yl}-n-(2-piperidin-1- yl-ethyl)-benzamide complex
  2phk		The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition
  2pk9		Structure of the pho85-pho80 cdk-cyclin complex of the phosphate-responsive signal transduction pathway
  2pkj		Crystal structure of f169a p38 kinase
  2pmi		Structure of the pho85-pho80 cdk-cyclin complex of the phosphate-responsive signal transduction pathway with bound atp-gamma-s
  2ptj		Crystal structure of f169r p38 kinase
  2pto		Mutagenesis of p38 map kinase establishes key roles of phe169 in function and dynamics and reveals a novel dfg- out state
  2puu		Crystal structure of p38 complex with 1-(5-tert-butyl-2-p- tolyl-2h-pyrazol-3-yl)-3-[4-(6-morpholin-4-ylmethyl- pyridin-3-yl)naphthalen-1-yl]urea
  2pv5		Mutagenesis of p38 map kinase establishes key roles of phe169 in function and structural dynamics and reveals a novel dfg-out state
  2pv8		Mutagenesis of p38 map kinase establishes key roles of phe169 in function and structural dynamics and reveals a novel dfg-out state
  2pvh		Structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2
  2pvj		Structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2
  2pvk		Structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2
  2pvl		Structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2
  2pvm		Structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2
  2pvn		Structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2
  2pvr		Crystal structure of the catalytic subunit of protein kinase ck2 (c-terminal deletion mutant 1-335) in complex with two sulfate ions
  2pzy		Structure of mk2 complexed with compound 76
  2q0n		Structure of human p21 activating kinase 4 (pak4) in complex with a consensus peptide
  2qc6		Protein kinase ck2 in complex with dbc
  2qcs		A complex structure between the catalytic and regulatory subunit of protein kinase a that represents the inhibited state
  2qd9		P38 alpha map kinase inhibitor based on heterobicyclic scaffolds
  2qg5		Cryptosporidium parvum calcium dependent protein kinase cgd7_1840
  2qhm		Crystal structure of chek1 in complex with inhibitor 2a
  2qhn		Crystal structure of chek1 in complex with inhibitor 1a
  2qkr		Cryptosporidium parvum cyclin-dependent kinase cgd5_2510 with indirubin 3'-monoxime bound
  2qnj		Kinase and ubiquitin-associated domains of mark3/par-1
  2qr7		2.0a x-ray structure of c-terminal kinase domain of p90 ribosomal s6 kinase 2: se-met derivative
  2qr8		2.0a x-ray structure of c-terminal kinase domain of p90 ribosomal s6 kinase 2 (rsk2)
  2qur		Crystal structure of f327a/k285p mutant of camp-dependent protein kinase
  2qvs		Crystal structure of type iia holoenzyme of camp-dependent protein kinase
  2r0i		Crystal structure of a kinase mark2/par-1 mutant
  2r0u		Crystal structure of chek1 in complex with inhibitor 54
  2r3f		Crystal structure of cyclin-dependent kinase 2 with inhibitor
  2r3g		Crystal structure of cyclin-dependent kinase 2 with inhibitor
  2r3h		Crystal structure of cyclin-dependent kinase 2 with inhibitor
  2r3i		Crystal structure of cyclin-dependent kinase 2 with inhibitor
  2r3j		Crystal structure of cyclin-dependent kinase 2 with inhibitor
  2r3k		Crystal structure of cyclin-dependent kinase 2 with inhibitor
  2r3l		Crystal structure of cyclin-dependent kinase 2 with inhibitor
  2r3m		Crystal structure of cyclin-dependent kinase 2 with inhibitor
  2r3n		Crystal structure of cyclin-dependent kinase 2 with inhibitor
  2r3o		Crystal structure of cyclin-dependent kinase 2 with inhibitor
  2r3p		Crystal structure of cyclin-dependent kinase 2 with inhibitor
  2r3q		Crystal structure of cyclin-dependent kinase 2 with inhibitor
  2r3r		Crystal structure of cyclin-dependent kinase 2 with inhibitor
  2r5t		Crystal structure of inactive serum and glucocorticoid- regulated kinase 1 in complex with amp-pnp
  2r64		Crystal structure of a 3-aminoindazole compound with cdk2
  2r7b		Crystal structure of the phosphoinositide-dependent kinase- (pdk-1)catalytic domain bound to a dibenzonaphthyridine inhibitor
  2r7i		Crystal structure of catalytic subunit of protein kinase ck2
  2r9s		C-jun n-terminal kinase 3 with 3,5-disubstituted quinoline inhibitor
  2rg5		Phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11b
  2rg6		Phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11j
  2rku		Structure of plk1 in complex with bi2536
  2uue		Replace: a strategy for iterative design of cyclin binding groove inhibitors
  2uv2		Crystal structure of human ste20-like kinase bound to 4-(4-( 5-cyclopropyl-1h-pyrazol-3-ylamino)-quinazolin-2-ylamino)- phenyl)-acetonitrile
  2uvx		Structure of pka-pkb chimera complexed with 7-azaindole
  2uvy		Structure of pka-pkb chimera complexed with methyl-(4-(9h- purin-6-yl)-benzyl)-amine
  2uvz		Structure of pka-pkb chimera complexed with c-phenyl-c-(4-( 9h-purin-6-yl)-phenyl)-methylamine
  2uw0		Structure of pka-pkb chimera complexed with 6-(4-(4-(4- chloro-phenyl)-piperidin-4-yl)-phenyl)-9h-purine
  2uw3		Structure of pka-pkb chimera complexed with 5-methyl-4- phenyl-1h-pyrazole
  2uw4		Structure of pka-pkb chimera complexed with 2-(4-(5-methyl- 1h-pyrazol-4-yl)-phenyl)-ethylamine
  2uw5		Structure of pka-pkb chimera complexed with (r)-2-(4- chloro-phenyl)-2-(4-1h-pyrazol-4-yl)-phenyl)-ethylamine
  2uw6		Structure of pka-pkb chimera complexed with (s)-2-(4- chloro-phenyl)-2-(4-1h-pyrazol-4-yl)-phenyl)-ethylamine
  2uw7		Structure of pka-pkb chimera complexed with 4-(4-chloro- phenyl)-4-(4-(1h-pyrazol-4-yl)-phenyl)-piperidine
  2uw8		Structure of pka-pkb chimera complexed with 2-(4-chloro- phenyl)-2-phenyl-ethylamine
  2uw9		Structure of pkb-beta (akt2) complexed with 4-(4-chloro- phenyl)-4-(4-(1h-pyrazol-4-yl)-phenyl)-piperidine
  2uzb		Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
  2uzd		Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
  2uze		Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
  2uzl		Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
  2uzn		Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
  2uzo		Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
  2uzt		Pka structures of akt, indazole-pyridine inhibitors
  2uzu		Pka structures of indazole-pyridine series of akt inhibitors
  2uzv		Pka structures of indazole-pyridine series of akt inhibitors
  2uzw		Pka structures of indazole-pyridine series of akt inhibitors
  2v0d		Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
  2v22		Replace: a strategy for iterative design of cyclin binding groove inhibitors
  2v55		Mechanism of multi-site phosphorylation from a rock-i:rhoe complex structure
  2v5q		Crystal structure of wild-type plk-1 kinase domain in complex with a selective darpin
  2v7o		Crystal structure of human calcium-calmodulin-dependent protein kinase ii gamma
  2vag		Crystal structure of di-phosphorylated human clk1 in complex with a novel substituted indole inhibitor
  2vd5		Structure of human myotonic dystrophy protein kinase in complex with the bisindoylmaleide inhibitor bim viii
  2vgo		Crystal structure of aurora b kinase in complex with reversine inhibitor
  2vgp		Crystal structure of aurora b kinase in complex with a aminothiazole inhibitor
  2vn9		Crystal structure of human calcium calmodulin dependent protein kinase ii delta isoform 1, camkd
  2vnw		Structure of pka-pkb chimera complexed with (1-(9h-purin-6- yl)piperidin-4-yl)methanamine
  2vny		Structure of pka-pkb chimera complexed with (1-(9h-purin-6- yl)piperidin-4-yl)amine
  2vo0		Structure of pka-pkb chimera complexed with c-(4-(4- chlorophenyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin- 4-yl)methylamine
  2vo3		Structure of pka-pkb chimera complexed with c-(4-(4- chlorophenyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin- 4-yl)methylamine
  2vo6		Structure of pka-pkb chimera complexed with 4-(4- chlorobenzyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin- 4-ylamine
  2vo7		Structure of pka complexed with 4-(4-chlorobenzyl)-1-(7h- pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-4-ylamine
  2vrx		Structure of aurora b kinase in complex with zm447439
  2vta		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
  2vth		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
  2vti		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
  2vtj		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
  2vtl		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
  2vtm		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
  2vtn		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
  2vto		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
  2vtp		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
  2vtq		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
  2vtr		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
  2vts		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
  2vtt		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
  2vu3		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
  2vv9		Cdk2 in complex with an imidazole piperazine
  2vwi		Structure of the osr1 kinase, a hypertension drug target
  2vx3		Crystal structure of the human dual specificity tyrosine- phosphorylation-regulated kinase 1a
  2vz6		Structure of human calcium calmodulin dependent protein kinase type ii alpha (camk2a) in complex with indirubin e804
  2w05		Structure of cdk2 in complex with an imidazolyl pyrimidine, compound 5b
  2w06		Structure of cdk2 in complex with an imidazolyl pyrimidine, compound 5c
  2w0j		Crystal structure of chk2 in complex with nsc 109555, a specific inhibitor
  2w17		Cdk2 in complex with the imidazole pyrimidine amide, compound (s)-8b
  2w1c		Structure determination of aurora kinase in complex with inhibitor
  2w1d		Structure determination of aurora kinase in complex with inhibitor
  2w1e		Structure determination of aurora kinase in complex with inhibitor
  2w1f		Structure determination of aurora kinase in complex with inhibitor
  2w1g		Structure determination of aurora kinase in complex with inhibitor
  2w1h		Fragment-based discovery of the pyrazol-4-yl urea (at9283), a multi-targeted kinase inhibitor with potent aurora kinase activity
  2w4o		Crystal structure of human camk4 in complex with 4-amino( sulfamoyl-phenylamino)-triazole-carbothioic acid (2,6- difluoro-phenyl)-amide)
  2w5a		Human nek2 kinase adp-bound
  2w5b		Human nek2 kinase atpgammas-bound
  2w5h		Human nek2 kinase apo
  2w7x		Cellular inhibition of checkpoint kinase 2 and potentiation of cytotoxic drugs by novel chk2 inhibitor pv1019
  2w96		Crystal structure of cdk4 in complex with a d-type cyclin
  2w99		Crystal structure of cdk4 in complex with a d-type cyclin
  2w9f		Crystal structure of cdk4 in complex with a d-type cyclin
  2w9z		Crystal structure of cdk4 in complex with a d-type cyclin
  2waj		Crystal structure of human jnk3 complexed with a 1-aryl-3,4- dihydroisoquinoline inhibitor
  2wei		Crystal structure of the kinase domain of cryptosporidium parvum calcium dependent protein kinase in complex with 3- mb-pp1
  2wel		Crystal structure of su6656-bound calcium/calmodulin- dependent protein kinase ii delta in complex with calmodulin
  2wev		Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design
  2wfy		Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design
  2wha		Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design
  2whb		Truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design
  2wih		Structure of cdk2-cyclin a with pha-848125
  2wip		Structure of cdk2-cyclin a complexed with 8-anilino-1- methyl-4,5-dihydro-1h-pyrazolo[4,3-h] quinazoline-3- carboxylic acid
  2wmq		Crystal structure of checkpoint kinase 1 (chk1) in complex with inhibitors
  2wmr		Crystal structure of checkpoint kinase 1 (chk1) in complex with inhibitors
  2wms		Crystal structure of checkpoint kinase 1 (chk1) in complex with inhibitors
  2wmt		Crystal structure of checkpoint kinase 1 (chk1) in complex with inhibitors
  2wmu		Crystal structure of checkpoint kinase 1 (chk1) in complex with inhibitors
  2wmv		Crystal structure of checkpoint kinase 1 (chk1) in complex with inhibitors
  2wmw		Crystal structure of checkpoint kinase 1 (chk1) in complex with inhibitors
  2wmx		Crystal structure of checkpoint kinase 1 (chk1) in complex with inhibitors
  2wnt		Crystal structure of the human ribosomal protein s6 kinase
  2wo6		Human dual-specificity tyrosine-phosphorylation-regulated kinase 1a in complex with a consensus substrate peptide
  2wqe		Structure of s155r aurora-a somatic mutant
  2wu6		Crystal structure of the human clk3 in complex with dki
  2wu7		Crystal structure of the human clk3 in complex with v25
  2ywp		Crystal structure of chk1 with a urea inhibitor
  2yza		Crystal structure of kinase domain of human 5'-amp- activated protein kinase alpha-2 subunit mutant (t172d)
  2z7l		Unphosphorylated mitogen activated protein kinase erk2 in complex with (4-{[5-carbamoyl-4-(3-methylanilino)pyrimidin 2-yl]amino}phenyl)acetic acid
  2z7q		Crystal structure of the n-terminal kinase domain of human rsk-1 bound to amp-pcp
  2z7r		Crystal structure of the n-terminal kinase domain of human rsk1 bound to staurosporine
  2z7s		Crystal structure of the n-terminal kinase domain of human rsk1 bound to purvalnol a
  2zaz		Crystal structure of p38 in complex with 4-anilino quinoline inhibitor
  2zb0		Crystal structure of p38 in complex with biphenyl amide inhibitor
  2zb1		Crystal structure of p38 in complex with biphenyl amide inhibitor
  2zdt		Crystal structure of human jnk3 complexed with an isoquinolone inhibitor
  2zdu		Crystal structure of human jnk3 complexed with an isoquinolone inhibitor
  2zjw		Crystal structure of human ck2 alpha complexed with ellagic acid
  2zmc		Crystal structure of human mitotic checkpoint kinase mps1 catalytic domain apo form
  2zmd		Crystal structure of human mps1 catalytic domain t686a mutant in complex with sp600125 inhibitor
  2zoq		Structural dissection of human mitogen-activated kinase erk1
  2zv2		Crystal structure of human calcium/calmodulin-dependent protein kinase kinase 2, beta, camkk2 kinase domain in complex with sto-609
  3a60		Crystal structure of unphosphorylated p70s6k1 (form i)
  3a61		Crystal structure of unphosphorylated p70s6k1 (form ii)
  3a62		Crystal structure of phosphorylated p70s6k1
  3be9		Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase ck2 and their anticancer activities
  3bgp		Human pim-1 complexed with a benzoisoxazole inhibitor vx1
  3bgq		Human pim-1 kinase in complex with an triazolo pyridazine inhibitor vx2
  3bgz		Human pim-1 kinase in complex with diphenyl indole inhibitor vx3
  3bhh		Crystal structure of human calcium/calmodulin-dependent protein kinase iib isoform 1 (camk2b)
  3bht		Structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor meriolin 3
  3bhu		Structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor meriolin 5
  3bhv		Structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor variolin b
  3bhy		Crystal structure of human death associated protein kinase (dapk3) in complex with a beta-carboline ligand
  3blh		Crystal structure of human cdk9/cyclint1
  3blq		Crystal structure of human cdk9/cyclint1 in complex with atp
  3blr		Crystal structure of human cdk9/cyclint1 in complex with flavopiridol
  3bqc		High ph-value crystal structure of emodin in complex with the catalytic subunit of protein kinase ck2
  3bqr		Crystal structure of human death associated protein kinase (dapk3) in complex with an imidazo-pyridazine ligand
  3bv2		Morpholino pyrrolotriazine p38 alpha map kinase inhibitor compound 30
  3bv3		Morpholino pyrrolotriazine p38 alpha map kinase inhibitor compound 2
  3bwf		Crystal structure of the human pim1 in complex with an osmium compound
  3bwj		Complex of pka with the bisubstrate protein kinase inhibitor lead compound arc-1034
  3bx5		P38 alpha map kinase complexed with bms-640994
  3c0g		Cask cam-kinase domain- 3'-amp complex, p1 form
  3c0h		Cask cam-kinase domain- amppnp complex, p1 form
  3c0i		Cask cam-kinase domain- 3'-amp complex, p212121 form
  3c13		Low ph-value crystal structure of emodin in complex with the catalytic subunit of protein kinase ck2
  3c4e		Pim-1 kinase domain in complex with 3-aminophenyl-7- azaindole
  3c4w		Crystal structure of g protein coupled receptor kinase 1 bound to atp and magnesium chloride at 2.7a
  3c4x		Crystal structure of g protein coupled receptor kinase 1 bound to atp and magnesium chloride at 2.9a
  3c4y		Crystal structure of apo form of g protein coupled receptor kinase 1 at 7.51a
  3c4z		Crystal structure of g protein coupled receptor kinase 1 bound to adp and magnesium chloride at 1.84a
  3c50		Crystal structure of g protein coupled receptor kinase 1 bound to adp and magnesium chloride at 2.6a
  3c51		Crystal structure of g protein coupled receptor kinase 1 bound to adp and magnesium chloride at 3.55a
  3c5u		P38 alpha map kinase complexed with a benzothiazole based inhibitor
  3c9w		Crystal structure of erk-2 with hypothemycin covalently bound
  3cek		Crystal structure of human dual specificity protein kinase (ttk)
  3cg2		P38 alpha kinase complexed with a pyrazolo-pyrimidine based inhibitor
  3cgf		Irak-4 inhibitors (part ii)- a structure based assessment of imidazo[1,2 a]pyridine binding
  3cgo		Irak-4 inhibitors (part ii)- a structure based assessment of imidazo[1,2 a]pyridine binding
  3cik		Human grk2 in complex with gbetagamma subunits
  3ckw		Crystal structure of sterile 20-like kinase 3 (mst3, stk24)
  3ckx		Crystal structure of sterile 20-like kinase 3 (mst3, stk24) in complex with staurosporine
  3coh		Crystal structure of aurora-a in complex with a pentacyclic inhibitor
  3coi		Crystal structure of p38delta kinase
  3cok		Crystal structure of plk4 kinase
  3com		Crystal structure of mst1 kinase
  3cqu		Crystal structure of akt-1 complexed with substrate peptide and inhibitor
  3cqw		Crystal structure of akt-1 complexed with substrate peptide and inhibitor
  3ctq		Structure of map kinase p38 in complex with a 1-o-tolyl-1,2, 3-triazole-4-carboxamide
  3cxw		Crystal structure of human proto-oncogene serine threonine kinase (pim1) in complex with a consensus peptide and a beta carboline ligand i
  3cy2		Crystal structure of human proto-oncogene serine threonine kinase (pim1) in complex with a consensus peptide and a beta carboline ligand ii
  3cy3		Crystal structure of human proto-oncogene serine threonine kinase (pim1) in complex with a consensus peptide and the jnk inhibitor v
  3d0e		Crystal structure of human akt2 in complex with gsk690693
  3d14		Crystal structure of mouse aurora a (asn186->gly, lys240- >arg, met302->leu) in complex with 1-{5-[2-(thieno[3,2- d]pyrimidin-4-ylamino)-ethyl]- thiazol-2-yl}-3-(3- trifluoromethyl-phenyl)-urea
  3d15		Crystal structure of mouse aurora a (asn186->gly, lys240- >arg, met302->leu) in complex with 1-(3-chloro-phenyl)-3- {5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)- ethyl]-thiazol-2- yl}-urea [sns-314]
  3d2i		Crystal structure of mouse aurora a (asn186->gly, lys240- >arg, met302->leu) in complex with 1-{5-[2-(1-methyl-1h- pyrazolo[4,3-d]pyrimidin-7-ylamino)-ethyl]-thiazol-2-yl}-3- (3-trifluoromethyl-phenyl)-urea
  3d2k		Crystal structure of mouse aurora a (asn186->gly, lys240- >arg, met302->leu) in complex with [7-(2-{2-[3-(3-chloro- phenyl)-ureido]-thiazol-5-yl}-ethylamino)-pyrazolo[4,3- d]pyrimidin-1-yl]-acetic acid
  3d5u		Crystal structure of a wildtype polo-like kinase 1 (plk1) catalytic domain.
  3d5v		Crystal structure of an activated (thr->asp) polo-like kinase 1 (plk1) catalytic domain.
  3d5w		Crystal structure of a phosphorylated polo-like kinase 1 (plk1) catalytic domain in complex with adp.
  3d5x		Crystal structure of an activated (thr->asp) polo-like kinase 1 (plk1) catalytic domain in complex with wortmannin.
  3d7z		Crystal structure of p38 kinase in complex with a biphenyl amide inhibitor
  3d83		Crystal structure of p38 kinase in complex with a biphenyl amide inhibitor
  3d9v		Crystal structure of rock i bound to h-1152p a di- methylated variant of fasudil
  3da6		Crystal structure of human jnk3 complexed with n-(3-methyl- 4-(3-(2-(methylamino)pyrimidin-4-yl)pyridin-2-yloxy) naphthalen-1-yl)-1h-benzo[d]imidazol-2-amine
  3dae		Crystal structure of phosphorylated snf1 kinase domain
  3daj		Crystal structure of aurora a complexed with an inhibitor discovered through site-directed dynamic tethering
  3dak		Crystal structure of domain-swapped osr1 kinase domain
  3db6		Crystal structure of an activated (thr->asp) polo-like kinase 1 (plk1) catalytic domain in complex with compound
  3db8		Crystal structure of an activated (thr->asp) polo-like kinase 1 (plk1) catalytic domain in complex with compound
  3dbc		Crystal structure of an activated (thr->asp) polo-like kinase 1 (plk1) catalytic domain in complex with compound
  3dbd		Crystal structure of an activated (thr->asp) polo-like kinase 1 (plk1) catalytic domain in complex with compound
  3dbe		Crystal structure of an activated (thr->asp) polo-like kinase 1 (plk1) catalytic domain in complex with compound
  3dbf		Crystal structure of an activated (thr->asp) polo-like kinase 1 (plk1) catalytic domain in complex with compound
  3dbq		Crystal structure of ttk kinase domain
  3dcv		Crystal structure of human pim1 kinase complexed with 4-(4- hydroxy-3-methyl-phenyl)-6-phenylpyrimidin-2(1h)-one
  3ddp		Structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor cr8
  3ddq		Structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor roscovitine
  3dfa		Crystal structure of kinase domain of calcium-dependent protein kinase cgd3_920 from cryptosporidium parvum
  3dfc		Crystal structure of a glycine-rich loop mutant of the death associated protein kinase catalytic domain with amppnp
  3dgk		Crystal structure of a glycine-rich loop mutant of the death associated protein kinase catalytic domain
  3dj5		Crystal structure of the mouse aurora-a catalytic domain (asn186->gly, lys240->arg, met302->leu) in complex with compound 290.
  3dj6		Crystal structure of the mouse aurora-a catalytic domain (asn186->gly, lys240->arg, met302->leu) in complex with compound 823.
  3dj7		Crystal structure of the mouse aurora-a catalytic domain (asn186->gly, lys240->arg, met302->leu) in complex with compound 130.
  3dls		Sgx clone 9501a6kwg1h1
  3dnd		Camp-dependent protein kinase pka catalytic subunit with pki-5-24
  3dne		Camp-dependent protein kinase pka catalytic subunit with pki-5-24
  3dog		Structure of thr 160 phosphorylated cdk2/cyclin a in complex with the inhibitor n-&-n1
  3ds6		P38 complex with a phthalazine inhibitor
  3dt1		P38 complexed with a quinazoline inhibitor
  3du8		Crystal structure of gsk-3 beta in complex with nms-869553a
  3dv3		Mek1 with pf-04622664 bound
  3dxn		Crystal structure of the calcium-dependent kinase from toxoplasma gondii, 541.m00134, kinase domain.
  3dy7		X-ray structure of the human mitogen-activated protein kinase kinase 1 (mek1) in a complex with ligand and mgatp
  3e3b		Crystal structure of catalytic subunit of human protein kinase ck2alpha prime with a potent indazole-derivative inhibitor
  3e3p		Glycogen synthase kinase from leishmania major
  3e5a		Crystal structure of aurora a in complex with vx-680 and tpx2
  3e7o		Crystal structure of jnk2
  3e87		Crystal structures of the kinase domain of akt2 in complex with atp-competitive inhibitors
  3e88		Crystal structures of the kinase domain of akt2 in complex with atp-competitive inhibitors
  3e8c		Crystal structures of the kinase domain of pka in complex with atp-competitive inhibitors
  3e8d		Crystal structures of the kinase domain of akt2 in complex with atp-competitive inhibitors
  3e8e		Crystal structures of the kinase domain of pka in complex with atp-competitive inhibitors
  3e8n		X-ray structure of the human mitogen-activated protein kinase kinase 1 (mek1) complexed with a potent inhibitor rdea119 and mgatp
  3e92		Crystal structure of p38 kinase in complex with a biaryl amide inhibitor
  3e93		Crystal structure of p38 kinase in complex with a biaryl amide inhibitor
  3eb0		Crystal structure of cgd4_240 from cryptosporidium parvum in complex with indirubin e804
  3efw		Structure of auroraa with pyridyl-pyrimidine urea inhibitor
  3eh9		Crystal structure of death associated protein kinase complexed with adp
  3eha		Crystal structure of death associated protein kinase complexed with amppnp
  3eid		Cdk2/cyclina complexed with a pyrazolopyridazine inhibitor
  3ej1		Cdk2/cyclina complexed with a pyrazolopyridazine inhibitor
  3elj		Jnk1 complexed with a bis-anilino-pyrrolopyrimidine inhibitor.
  3enm		The structure of the map2k mek6 reveals an autoinhibitory dimer
  3eoc		Cdk2/cyclina complexed with a imidazo triazin-2-amine
  3eqb		X-ray structure of the human mitogen-activated protein kinase kinase 1 (mek1) in a complex with ligand and mgatp
  3eqc		X-ray structure of the human mitogen-activated protein kinase kinase 1 (mek1) in a ternary complex with compound 1, atp-gs and mg2p
  3eqd		X-ray structure of the human mitogen-activated protein kinase kinase 1 (mek1) in a binary complex with atp-gs and mg2p
  3eqf		X-ray structure of the human mitogen-activated protein kinase kinase 1 (mek1) in a binary complex with k252a and mg2p
  3eqg		X-ray structure of the human mitogen-activated protein kinase kinase 1 (mek1) in a ternary complex with pd, adp and mg2p
  3eqh		X-ray structure of the human mitogen-activated protein kinase kinase 1 (mek1) in a ternary complex with u0126, adp and mg2p
  3eqi		X-ray structure of the human mitogen-activated protein kinase kinase 1 (mek1) in a binary complex with adp and mg2p
  3erk		The complex structure of the map kinase erk2/sb220025
  3ezr		Cdk-2 with indazole inhibitor 17 bound at its active site
  3ezv		Cdk-2 with indazole inhibitor 9 bound at its active site
  3f2a		Crystal structure of human pim-1 in complex with dappa
  3f3z		Crystal structure of cryptosporidium parvum calcium dependent protein kinase cgd7_1840 in presence of indirubin e804
  3f5g		Crystal structure of death associated protein kinase in complex with adp and mg2+
  3f5u		Crystal structure of the death associated protein kinase in complex with amppnp and mg2+
  3f5x		Cdk-2-cyclin complex with indazole inhibitor 9 bound at its active site
  3f61		Crystal structure of m. tuberculosis pknb leu33asp/val222asp double mutant in complex with adp
  3f69		Crystal structure of the mycobacterium tuberculosis pknb mutant kinase domain in complex with kt5720
  3f7z		X-ray co-crystal structure of glycogen synthase kinase 3beta in complex with an inhibitor
  3f88		Glycogen synthase kinase 3beta inhibitor complex
  3f9n		Crystal structure of chk1 kinase in complex with inhibitor
  3fc1		Crystal structure of p38 kinase bound to pyrimido- pyridazinone inhibitor
  3fc2		Plk1 in complex with bi6727
  3fdn		Structure-based drug design of novel aurora kinase a inhibitors: structure basis for potency and specificity
  3fe3		Crystal structure of the kinase mark3/par-1: t211a-s215a double mutant
  3fhi		Crystal structure of a complex between the catalytic and regulatory (ri{alpha}) subunits of pka
  3fi2		Crystal structure of jnk3 with amino-pyrazole inhibitor, sr-
  3fi3		Crystal structure of jnk3 with indazole inhibitor, sr-3737
  3fjq		Crystal structure of camp-dependent protein kinase catalytic subunit alpha in complex with peptide inhibitor pki alpha (6-25)
  3fl5		Protein kinase ck2 in complex with the inhibitor quinalizarin
  3fme		Crystal structure of human mitogen-activated protein kinase kinase 6 (mek6) activated mutant (s207d, t211d)
  3fpm		Crystal structure of a squarate inhibitor bound to mapkap kinase-2
  3fv8		Jnk3 bound to piperazine amide inhibitor, sr2774.
  3fwq		Inactive conformation of human protein kinase ck2 catalytic subunit
  3fxz		Crystal structure of pak1 kinase domain with ruthenium complex lambda-fl172
  3fy0		Crystal structure of pak1 kinase domain with ruthenium complex dw1
  3fyj		Crystal structure of an optimzied benzothiophene inhibitor bound to mapkap kinase-2 (mk-2)
  3fyk		Crystal structure of a benzthiophene lead bound to mapkap kinase-2 (mk-2)
  3fz1		Crystal structure of a benzthiophene inhibitor bound to human cyclin-dependent kinase-2 (cdk-2)
  3g33		Crystal structure of cdk4/cyclin d3
  3g90		Jnk-3 bound to (z)-5-fluoro-1-((6-fluoro-4h-benzo[d][1, 3]dioxin-8-yl)methyl)-3-(hydroxyimino)indolin-2-one
  3g9l		Jnk3 bound to (z)-1-((6-fluoro-4h-benzo[d][1,3]dioxin-8-yl) methyl)-3-(hydroxyimino)-4-styrylindolin-2-one
  3g9n		Jnk3 bound to (z)-1-((6-fluoro-4h-benzo[d][1,3]dioxin-8-yl) methyl)-3-(hydroxyimino)-4-phenylindolin-2-one
  3gbz		Structure of the cmgc cdk kinase from giardia lamblia
  3gc0		Structure of the cmgc cdk kinase from giardia lamblia in complex with amp
  3gc7		The structure of p38alpha in complex with a dihydroquinazolinone
  3gc8		The structure of p38beta c162s in complex with a dihydroquinazolinone
  3gc9		The structure of p38beta c119s, c162s in complex with a dihydroquinazolinone inhibitor
  3gcp		Human p38 map kinase in complex with sb203580
  3gcq		Human p38 map kinase in complex with rl45
  3gcs		Human p38 map kinase in complex with sorafenib
  3gcu		Human p38 map kinase in complex with rl48
  3gcv		Human p38 map kinase in complex with rl62
  3gfe		Crystal structure of p38a mitogen-activated protein kinase in complex with a pyrazolopyridinone inhibitor
  3gfw		Crystal structure of human dual specificity protein kinase (ttk) in complex with a pyrolo-pyridin ligand
  3ggf		Crystal structure of human serine/threonine-protein kinase mst4 in complex with an quinazolin
  3gi3		Crystal structure of a n-phenyl-n'-naphthylurea analog in complex with p38 map kinase
  3gp0		Crystal structure of human mitogen activated protein kinase (p38 beta) in complex with nilotinib
  3h0y		Aurora a in complex with a bisanilinopyrimidine
  3h0z		Aurora a in complex with a bisanilinopyrimidine
  3h10		Aurora a inhibitor complex
  3h30		Crystal structure of the catalytic subunit of human protein kinase ck2 with 5,6-dichloro-1-beta-d- ribofuranosylbenzimidazole
  3h4j		Crystal structure of pombe ampk kdaid fragment
  3h9f		Crystal structure of human dual specificity protein kinase (ttk) in complex with a pyrimido-diazepin ligand
  3h9o		Phosphoinositide-dependent protein kinase 1 (pdk-1) in complex with compound 9
  3ha6		Crystal structure of aurora a in complex with tpx2 and compound 10
  3ha8		The complex structure of the map kinase p38/compound 14b
  3hdm		Crystal structure of serum and glucocorticoid-regulated kinase 1 in complex with compound 1
  3hdn		Crystal structure of serum and glucocorticoid-regulated kinase 1 in complex with compound 2
  3hec		P38 in complex with imatinib
  3heg		P38 in complex with sorafenib
  3hko		Crystal structure of a cdpk kinase domain from cryptosporidium parvum, cgd7_40
  3hl7		Crystal structure of human p38alpha complexed with sd-0006
  3hll		Crystal structure of human p38alpha complexed with ph-797804
  3hp2		Crystal structure of human p38alpha complexed with a pyridinone compound
  3hp5		Crystal structure of human p38alpha complexed with a pyrimidopyridazinone compound
  3hrb		P38 kinase crystal structure in complex with small molecule inhibitor
  3hrc		Crystal structure of a mutant of human pdk1 kinase domain in complex with atp
  3hrf		Crystal structure of human pdk1 kinase domain in complex with an allosteric activator bound to the pif-pocket
  3hv3		Human p38 map kinase in complex with rl49
  3hv4		Human p38 map kinase in complex with rl51
  3hv5		Human p38 map kinase in complex with rl24
  3hv6		Human p38 map kinase in complex with rl39
  3hv7		Human p38 map kinase in complex with rl38
  3hvc		Crystal structure of human p38alpha map kinase
  3hx4		Crystal structure of cdpk1 of toxoplasma gondii, tgme49_101440, in presence of calcium
  3hyh		Crystal structure of the protein kinase domain of yeast amp- activated protein kinase snf1
  3hzt		Crystal structure of toxoplasma gondii cdpk3, tgme49_105860
  3i6u		Structure and activation mechanism of the chk2 dna-damage checkpoint kinase
  3i6w		Structure and activation mechanism of the chk2 dna-damage checkpoint kinase
  3i79		Calcium-dependent protein kinase 1 from toxoplasma gondii (tgcdpk1)
  3idb		Crystal structure of (108-268)riib:c holoenzyme of camp- dependent protein kinase
  3idc		Crystal structure of (102-265)riib:c holoenzyme of camp- dependent protein kinase
  3ig7		Novel cdk-5 inhibitors - crystal structure of inhibitor efp with cdk-2
  3igg		Novel cdk-5 inhibitors - crystal structure of inhibitor efq with cdk-2
  3igo		Crystal structure of cryptosporidium parvum cdpk1, cgd3_920
  3iph		Crystal structure of p38 in complex with a biphenylamide inhibitor
  3is5		Crystal structure of cdpk kinase domain from toxoplasma gondii, tgme49_018720
  3iw4		Crystal structure of pkc alpha in complex with nvp-aeb071
  3iw5		Human p38 map kinase in complex with an indole derivative
  3iw6		Human p38 map kinase in complex with a benzylpiperazin- pyrrol
  3iw7		Human p38 map kinase in complex with an imidazo-pyridine
  3iw8		Structure of inactive human p38 map kinase in complex with a thiazole-urea
  3jpv		Crystal structure of human proto-oncogene serine threonine kinase (pim1) in complex with a consensus peptide and a pyrrolo[2,3-a]carbazole ligand
  3juh		Crystal structure of a mutant of human protein kinase ck2alpha with altered cosubstrate specificity
  3jvr		Characterization of the chk1 allosteric inhibitor binding site
  3jvs		Characterization of the chk1 allosteric inhibitor binding site
  3jxw		Discovery of 3h-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective and orally bioavailable pim kinases inhibitors
  3jy0		Discovery of 3h-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective and orally bioavailable pim kinases inhibitors
  3jya		Discovery of 3h-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective and orally bioavailable pim kinases inhibitors
  3k2l		Crystal structure of dual-specificity tyrosine phosphorylation regulated kinase 2 (dyrk2)
  3k3i		P38alpha bound to novel dgf-out compound pf-00215955
  3k3j		P38alpha bound to novel dfg-out compound pf-00416121
  4erk		The complex structure of the map kinase erk2/olomoucine

• Links (links to other resources describing this domain)

• PFAM	pkinase
  INTERPRO	IPR002290

Send comments to Ivica Letunic